primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
101726503,10172650,1,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"2 MG, QWK",,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q1,Abortion spontaneous,,2016,Q1,3,F,20140420.0,20160127.0,20140515,20160210,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20611794,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,82.54,KG,20160210.0,,OT,US,US,2016,Q1,Adult
101726503,10172650,1,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"2 MG, QWK",,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q1,Pregnancy on contraceptive,,2016,Q1,3,F,20140420.0,20160127.0,20140515,20160210,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20611794,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,82.54,KG,20160210.0,,OT,US,US,2016,Q1,Adult
101726503,10172650,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"5 ?G, BID",,,,,,,,5.0,UG,POWDER FOR SUSPENSION FOR INJECTION,BID,2016,Q1,Abortion spontaneous,,2016,Q1,3,F,20140420.0,20160127.0,20140515,20160210,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20611794,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,82.54,KG,20160210.0,,OT,US,US,2016,Q1,Adult
101726503,10172650,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"5 ?G, BID",,,,,,,,5.0,UG,POWDER FOR SUSPENSION FOR INJECTION,BID,2016,Q1,Pregnancy on contraceptive,,2016,Q1,3,F,20140420.0,20160127.0,20140515,20160210,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20611794,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,82.54,KG,20160210.0,,OT,US,US,2016,Q1,Adult
108721525,10872152,18,C,EXENATIDE MICROSPHERES,,2,Oral,,,,,,,,,,,,,2016,Q1,Non-cardiac chest pain,Non-cardiac chest pain,2016,Q1,5,F,20150103.0,20160108.0,20150226,20160112,PER,,US-EISAI MEDICAL RESEARCH-EC-2015-003422,EISAI,,57.0,YR,,M,Y,128.8,KG,20160112.0,,MD,US,US,2016,Q1,Adult
108721525,10872152,18,C,EXENATIDE MICROSPHERES,,2,Oral,,,,,,,,,,,,,2016,Q1,Upper respiratory tract infection,,2016,Q1,5,F,20150103.0,20160108.0,20150226,20160112,PER,,US-EISAI MEDICAL RESEARCH-EC-2015-003422,EISAI,,57.0,YR,,M,Y,128.8,KG,20160112.0,,MD,US,US,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Abdominal pain,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Acute kidney injury,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Distributive shock,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Encephalopathy,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Haemodynamic instability,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Hypoglycaemia,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Intentional overdose,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Metabolic acidosis,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Pulmonary hypertension,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Respiratory failure,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Right ventricular dysfunction,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113264725,11326472,3,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q1,Vomiting,,2016,Q1,5,F,,20151223.0,20150731,20160106,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049449,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20160106.0,,OT,AU,AU,2016,Q1,Adult
113973732,11397373,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q1,Asthma,,2016,Q1,2,F,20150807.0,20160111.0,20150819,20160119,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20160119.0,,,US,US,2016,Q1,Elderly
113973732,11397373,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q1,Blood glucose increased,,2016,Q1,2,F,20150807.0,20160111.0,20150819,20160119,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20160119.0,,,US,US,2016,Q1,Elderly
113973732,11397373,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q1,Drug dose omission,,2016,Q1,2,F,20150807.0,20160111.0,20150819,20160119,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20160119.0,,,US,US,2016,Q1,Elderly
113973732,11397373,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q1,Feeling abnormal,,2016,Q1,2,F,20150807.0,20160111.0,20150819,20160119,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20160119.0,,,US,US,2016,Q1,Elderly
113973732,11397373,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q1,Intentional product misuse,,2016,Q1,2,F,20150807.0,20160111.0,20150819,20160119,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20160119.0,,,US,US,2016,Q1,Elderly
113973732,11397373,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q1,Weight decreased,,2016,Q1,2,F,20150807.0,20160111.0,20150819,20160119,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20160119.0,,,US,US,2016,Q1,Elderly
117051534,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2016,Q1,Acute kidney injury,,2016,Q1,4,F,20150416.0,20160303.0,20151106,20160310,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160310.0,,CN,US,US,2016,Q1,Elderly
117051534,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2016,Q1,Cardiac failure congestive,,2016,Q1,4,F,20150416.0,20160303.0,20151106,20160310,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160310.0,,CN,US,US,2016,Q1,Elderly
117051534,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2016,Q1,Cholecystitis acute,,2016,Q1,4,F,20150416.0,20160303.0,20151106,20160310,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160310.0,,CN,US,US,2016,Q1,Elderly
117051534,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2016,Q1,Pancreatitis acute,,2016,Q1,4,F,20150416.0,20160303.0,20151106,20160310,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160310.0,,CN,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Abdominal distension,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Ankle fracture,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Blood electrolytes decreased,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Blood glucose increased,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Cardiac disorder,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Chronic kidney disease,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Constipation,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Decreased appetite,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Diarrhoea,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Drug dose omission,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Dry skin,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Ear congestion,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Face injury,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Fall,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Gastroenteritis viral,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Increased appetite,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Injection site mass,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Injection site nodule,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Nausea,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Skin irritation,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Vomiting,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118238052,11823805,13,C,EXENATIDE,EXENATIDE,1,,"5MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,,,2016,Q1,Weight decreased,,2016,Q1,2,F,201108.0,20160212.0,20151210,20160219,EXP,,US-ASTRAZENECA-2013SE28384,ASTRAZENECA,,728.0,MON,,F,Y,72.6,KG,20160219.0,,,US,US,2016,Q1,Elderly
118272752,11827275,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Acute kidney injury,,2016,Q1,2,F,20150416.0,20160303.0,20151211,20160311,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-62633YA",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,114.0,KG,20160311.0,,MD,COUNTRY NOT SPECIFIED,US,2016,Q1,Elderly
118272752,11827275,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Cardiac failure congestive,,2016,Q1,2,F,20150416.0,20160303.0,20151211,20160311,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-62633YA",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,114.0,KG,20160311.0,,MD,COUNTRY NOT SPECIFIED,US,2016,Q1,Elderly
118272752,11827275,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Cholecystitis acute,,2016,Q1,2,F,20150416.0,20160303.0,20151211,20160311,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-62633YA",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,114.0,KG,20160311.0,,MD,COUNTRY NOT SPECIFIED,US,2016,Q1,Elderly
118272752,11827275,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Pancreatitis acute,,2016,Q1,2,F,20150416.0,20160303.0,20151211,20160311,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-62633YA",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,114.0,KG,20160311.0,,MD,COUNTRY NOT SPECIFIED,US,2016,Q1,Elderly
118873781,11887378,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Injection site bruising,,2016,Q1,1,I,,20120511.0,20160104,20160104,PER,,US-ASTRAZENECA-2012BM08746,ASTRAZENECA,,63.0,YR,,F,Y,,,20160105.0,,CN,US,US,2016,Q1,Adult
118873781,11887378,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Injection site haemorrhage,,2016,Q1,1,I,,20120511.0,20160104,20160104,PER,,US-ASTRAZENECA-2012BM08746,ASTRAZENECA,,63.0,YR,,F,Y,,,20160105.0,,CN,US,US,2016,Q1,Adult
118873781,11887378,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Product quality issue,,2016,Q1,1,I,,20120511.0,20160104,20160104,PER,,US-ASTRAZENECA-2012BM08746,ASTRAZENECA,,63.0,YR,,F,Y,,,20160105.0,,CN,US,US,2016,Q1,Adult
118910571,11891057,2,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Influenza,,2016,Q1,1,I,2006.0,20080702.0,20160106,20160106,PER,,US-ASTRAZENECA-2008BM09232,ASTRAZENECA,,64.0,YR,,F,Y,80.7,KG,20160106.0,,,US,US,2016,Q1,Adult
118910571,11891057,2,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Weight decreased,,2016,Q1,1,I,2006.0,20080702.0,20160106,20160106,PER,,US-ASTRAZENECA-2008BM09232,ASTRAZENECA,,64.0,YR,,F,Y,80.7,KG,20160106.0,,,US,US,2016,Q1,Adult
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Acute kidney injury,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Haematoma,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Internal haemorrhage,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Lactic acidosis,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Peripheral vascular disorder,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Puncture site haemorrhage,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118929392,11892939,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q1,Sepsis syndrome,,2016,Q1,2,F,201412.0,20160229.0,20160106,20160314,EXP,,US-JNJFOC-20160100709,JANSSEN,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
118954551,11895455,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Acidosis,,2016,Q1,1,I,20151025.0,,20160106,20160106,DIR,,,,,47.0,YR,,M,N,241.0,LBS,20160105.0,N,,US,,2016,Q1,Adult
118954551,11895455,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Diarrhoea,,2016,Q1,1,I,20151025.0,,20160106,20160106,DIR,,,,,47.0,YR,,M,N,241.0,LBS,20160105.0,N,,US,,2016,Q1,Adult
118954551,11895455,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Glycosylated haemoglobin increased,,2016,Q1,1,I,20151025.0,,20160106,20160106,DIR,,,,,47.0,YR,,M,N,241.0,LBS,20160105.0,N,,US,,2016,Q1,Adult
118954551,11895455,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Malaise,,2016,Q1,1,I,20151025.0,,20160106,20160106,DIR,,,,,47.0,YR,,M,N,241.0,LBS,20160105.0,N,,US,,2016,Q1,Adult
118954551,11895455,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Nausea,,2016,Q1,1,I,20151025.0,,20160106,20160106,DIR,,,,,47.0,YR,,M,N,241.0,LBS,20160105.0,N,,US,,2016,Q1,Adult
118954551,11895455,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Vomiting,,2016,Q1,1,I,20151025.0,,20160106,20160106,DIR,,,,,47.0,YR,,M,N,241.0,LBS,20160105.0,N,,US,,2016,Q1,Adult
119036861,11903686,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Injection site bruising,,2016,Q1,1,I,201512.0,20111229.0,20160110,20160110,PER,,US-ASTRAZENECA-2011BM13072,ASTRAZENECA,,681.0,MON,,F,Y,79.4,KG,20160111.0,,,US,US,2016,Q1,Elderly
119036861,11903686,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Injection site haemorrhage,,2016,Q1,1,I,201512.0,20111229.0,20160110,20160110,PER,,US-ASTRAZENECA-2011BM13072,ASTRAZENECA,,681.0,MON,,F,Y,79.4,KG,20160111.0,,,US,US,2016,Q1,Elderly
119036861,11903686,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Injection site mass,,2016,Q1,1,I,201512.0,20111229.0,20160110,20160110,PER,,US-ASTRAZENECA-2011BM13072,ASTRAZENECA,,681.0,MON,,F,Y,79.4,KG,20160111.0,,,US,US,2016,Q1,Elderly
119036861,11903686,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Product quality issue,,2016,Q1,1,I,201512.0,20111229.0,20160110,20160110,PER,,US-ASTRAZENECA-2011BM13072,ASTRAZENECA,,681.0,MON,,F,Y,79.4,KG,20160111.0,,,US,US,2016,Q1,Elderly
119036861,11903686,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Underdose,,2016,Q1,1,I,201512.0,20111229.0,20160110,20160110,PER,,US-ASTRAZENECA-2011BM13072,ASTRAZENECA,,681.0,MON,,F,Y,79.4,KG,20160111.0,,,US,US,2016,Q1,Elderly
119362451,11936245,7,C,EXENATIDE,EXENATIDE,1,,USE AS DIRECTED,,,,,,,,,,,/wk,2016,Q1,Hypersensitivity,,2016,Q1,1,I,20151104.0,20160111.0,20160121,20160121,EXP,GB-MHRA-TPP14975542C1524575YC1448646804676,GB-TEVA-625339ACC,TEVA,,63.0,YR,,F,Y,70.0,KG,20160121.0,,MD,GB,GB,2016,Q1,Adult
119362451,11936245,7,C,EXENATIDE,EXENATIDE,1,,USE AS DIRECTED,,,,,,,,,,,/wk,2016,Q1,Stevens-Johnson syndrome,,2016,Q1,1,I,20151104.0,20160111.0,20160121,20160121,EXP,GB-MHRA-TPP14975542C1524575YC1448646804676,GB-TEVA-625339ACC,TEVA,,63.0,YR,,F,Y,70.0,KG,20160121.0,,MD,GB,GB,2016,Q1,Adult
119362451,11936245,7,C,EXENATIDE,EXENATIDE,1,,USE AS DIRECTED,,,,,,,,,,,/wk,2016,Q1,Urticaria,,2016,Q1,1,I,20151104.0,20160111.0,20160121,20160121,EXP,GB-MHRA-TPP14975542C1524575YC1448646804676,GB-TEVA-625339ACC,TEVA,,63.0,YR,,F,Y,70.0,KG,20160121.0,,MD,GB,GB,2016,Q1,Adult
119445541,11944554,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Blood glucose decreased,,2016,Q1,1,I,2006.0,20080403.0,20160125,20160125,PER,,US-ASTRAZENECA-2008BM04885,ASTRAZENECA,,63.0,YR,,F,Y,,,20160125.0,,CN,US,US,2016,Q1,Adult
119445541,11944554,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Nausea,,2016,Q1,1,I,2006.0,20080403.0,20160125,20160125,PER,,US-ASTRAZENECA-2008BM04885,ASTRAZENECA,,63.0,YR,,F,Y,,,20160125.0,,CN,US,US,2016,Q1,Adult
119445541,11944554,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Product quality issue,,2016,Q1,1,I,2006.0,20080403.0,20160125,20160125,PER,,US-ASTRAZENECA-2008BM04885,ASTRAZENECA,,63.0,YR,,F,Y,,,20160125.0,,CN,US,US,2016,Q1,Adult
119445541,11944554,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Vomiting,,2016,Q1,1,I,2006.0,20080403.0,20160125,20160125,PER,,US-ASTRAZENECA-2008BM04885,ASTRAZENECA,,63.0,YR,,F,Y,,,20160125.0,,CN,US,US,2016,Q1,Adult
119667541,11966754,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,U,,,21773.0,2.0,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/month,2016,Q1,Drug dose omission,,2016,Q1,1,I,201408.0,20141231.0,20160127,20160127,EXP,,US-ASTRAZENECA-2015SE03276,ASTRAZENECA,,708.0,MON,,F,Y,,,20160127.0,,CN,US,US,2016,Q1,Elderly
119667541,11966754,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,U,,,21773.0,2.0,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/month,2016,Q1,Liver disorder,,2016,Q1,1,I,201408.0,20141231.0,20160127,20160127,EXP,,US-ASTRAZENECA-2015SE03276,ASTRAZENECA,,708.0,MON,,F,Y,,,20160127.0,,CN,US,US,2016,Q1,Elderly
119667541,11966754,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,U,,,21773.0,2.0,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/month,2016,Q1,Pneumonia,,2016,Q1,1,I,201408.0,20141231.0,20160127,20160127,EXP,,US-ASTRAZENECA-2015SE03276,ASTRAZENECA,,708.0,MON,,F,Y,,,20160127.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Abasia,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Asthenia,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Blood glucose increased,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Device issue,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Dysstasia,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Fatigue,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Injection site discolouration,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Injection site hypertrophy,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Injection site induration,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Injection site nodule,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Injection site pain,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Intentional device misuse,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Scar,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
119886902,11988690,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Sciatica,,2016,Q1,2,F,2012.0,20160222.0,20160202,20160301,EXP,,US-ASTRAZENECA-2014SE31294,ASTRAZENECA,,67.0,YR,,F,Y,81.2,KG,20160301.0,,CN,US,US,2016,Q1,Elderly
120429761,12042976,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Blood glucose increased,,2016,Q1,1,I,200805.0,20080908.0,20160208,20160208,PER,,US-ASTRAZENECA-2008BM12807,ASTRAZENECA,,676.0,MON,,F,Y,,,20160208.0,,,US,US,2016,Q1,Elderly
120429761,12042976,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Decreased appetite,,2016,Q1,1,I,200805.0,20080908.0,20160208,20160208,PER,,US-ASTRAZENECA-2008BM12807,ASTRAZENECA,,676.0,MON,,F,Y,,,20160208.0,,,US,US,2016,Q1,Elderly
120429761,12042976,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Fungal infection,,2016,Q1,1,I,200805.0,20080908.0,20160208,20160208,PER,,US-ASTRAZENECA-2008BM12807,ASTRAZENECA,,676.0,MON,,F,Y,,,20160208.0,,,US,US,2016,Q1,Elderly
120429761,12042976,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Nausea,,2016,Q1,1,I,200805.0,20080908.0,20160208,20160208,PER,,US-ASTRAZENECA-2008BM12807,ASTRAZENECA,,676.0,MON,,F,Y,,,20160208.0,,,US,US,2016,Q1,Elderly
120429761,12042976,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Pruritus,,2016,Q1,1,I,200805.0,20080908.0,20160208,20160208,PER,,US-ASTRAZENECA-2008BM12807,ASTRAZENECA,,676.0,MON,,F,Y,,,20160208.0,,,US,US,2016,Q1,Elderly
120429761,12042976,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Weight decreased,,2016,Q1,1,I,200805.0,20080908.0,20160208,20160208,PER,,US-ASTRAZENECA-2008BM12807,ASTRAZENECA,,676.0,MON,,F,Y,,,20160208.0,,,US,US,2016,Q1,Elderly
120457691,12045769,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 72923,,22200.0,2.0,MG,,/wk,2016,Q1,Injection site discharge,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 72923,,22200.0,2.0,MG,,/wk,2016,Q1,Lymphoedema,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 72923,,22200.0,2.0,MG,,/wk,2016,Q1,Product quality issue,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 72923,,22200.0,2.0,MG,,/wk,2016,Q1,Upper limb fracture,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,3,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,22200.0,2.0,MG,,/wk,2016,Q1,Injection site discharge,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,3,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,22200.0,2.0,MG,,/wk,2016,Q1,Lymphoedema,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,3,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,22200.0,2.0,MG,,/wk,2016,Q1,Product quality issue,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120457691,12045769,3,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,22200.0,2.0,MG,,/wk,2016,Q1,Upper limb fracture,,2016,Q1,1,I,20121108.0,20121109.0,20160208,20160208,EXP,,US-ASTRAZENECA-2012BM14759,ASTRAZENECA,,25545.0,DY,,F,Y,113.4,KG,20160208.0,,CN,US,US,2016,Q1,Elderly
120525011,12052501,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,MAMY MONTHS-YEARS 10 MCG BID SUBCUTANEOUS,,,D,D,,,,10.0,UG,,BID,2016,Q1,Hypoglycaemia,,2016,Q1,1,I,20160205.0,,20160208,20160208,DIR,,,,,38.0,YR,,M,N,,,20160205.0,N,MD,US,,2016,Q1,Adult
120556311,12055631,9,C,EXENATIDE,EXENATIDE,1,,5 UG PEN DISPOSABLE PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Constipation,,2016,Q1,1,I,20090417.0,20090427.0,20160209,20160209,PER,,US-ASTRAZENECA-2009BM05324,ASTRAZENECA,,22464.0,DY,,F,Y,250.0,KG,20160210.0,,,US,US,2016,Q1,Elderly
120556311,12055631,9,C,EXENATIDE,EXENATIDE,1,,5 UG PEN DISPOSABLE PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Sleep apnoea syndrome,,2016,Q1,1,I,20090417.0,20090427.0,20160209,20160209,PER,,US-ASTRAZENECA-2009BM05324,ASTRAZENECA,,22464.0,DY,,F,Y,250.0,KG,20160210.0,,,US,US,2016,Q1,Elderly
120556311,12055631,9,C,EXENATIDE,EXENATIDE,1,,5 UG PEN DISPOSABLE PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Visual acuity reduced,,2016,Q1,1,I,20090417.0,20090427.0,20160209,20160209,PER,,US-ASTRAZENECA-2009BM05324,ASTRAZENECA,,22464.0,DY,,F,Y,250.0,KG,20160210.0,,,US,US,2016,Q1,Elderly
120556311,12055631,9,C,EXENATIDE,EXENATIDE,1,,5 UG PEN DISPOSABLE PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Weight decreased,,2016,Q1,1,I,20090417.0,20090427.0,20160209,20160209,PER,,US-ASTRAZENECA-2009BM05324,ASTRAZENECA,,22464.0,DY,,F,Y,250.0,KG,20160210.0,,,US,US,2016,Q1,Elderly
121094601,12109460,1,PS,EXENATIDE 10MG LILLY,EXENATIDE,1,Subcutaneous,,,,N,D,,20170215,,10.0,UG,,BID,2016,Q1,Hepatic cancer metastatic,,2016,Q1,1,I,20160218.0,,20160222,20160222,DIR,,,,,62.0,YR,,M,N,196.0,LBS,20160219.0,N,MD,US,,2016,Q1,Adult
121094601,12109460,1,PS,EXENATIDE 10MG LILLY,EXENATIDE,1,Subcutaneous,,,,N,D,,20170215,,10.0,UG,,BID,2016,Q1,Neuroendocrine tumour,,2016,Q1,1,I,20160218.0,,20160222,20160222,DIR,,,,,62.0,YR,,M,N,196.0,LBS,20160219.0,N,MD,US,,2016,Q1,Adult
121181791,12118179,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 9RK79M,,21773.0,5.0,UG,,BID,2016,Q1,Blood cholesterol increased,,2016,Q1,1,I,20061018.0,20061031.0,20160226,20160226,PER,,US-ASTRAZENECA-2006BM17345,ASTRAZENECA,,67.0,YR,,F,Y,,,20160226.0,,CN,US,US,2016,Q1,Elderly
121181791,12118179,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 9RK79M,,21773.0,5.0,UG,,BID,2016,Q1,Drug dose omission,,2016,Q1,1,I,20061018.0,20061031.0,20160226,20160226,PER,,US-ASTRAZENECA-2006BM17345,ASTRAZENECA,,67.0,YR,,F,Y,,,20160226.0,,CN,US,US,2016,Q1,Elderly
121181791,12118179,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 9RK79M,,21773.0,5.0,UG,,BID,2016,Q1,Intentional product misuse,,2016,Q1,1,I,20061018.0,20061031.0,20160226,20160226,PER,,US-ASTRAZENECA-2006BM17345,ASTRAZENECA,,67.0,YR,,F,Y,,,20160226.0,,CN,US,US,2016,Q1,Elderly
121181791,12118179,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, 9RK79M,,21773.0,5.0,UG,,BID,2016,Q1,Pain in extremity,,2016,Q1,1,I,20061018.0,20061031.0,20160226,20160226,PER,,US-ASTRAZENECA-2006BM17345,ASTRAZENECA,,67.0,YR,,F,Y,,,20160226.0,,CN,US,US,2016,Q1,Elderly
121421711,12142171,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q1,Drug ineffective,,2016,Q1,1,I,20160224.0,20160226.0,20160303,20160303,PER,,US-BAYER-2016-039295,BAYER,,71.0,YR,E,F,Y,82.99,KG,20160303.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Acute kidney injury,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Haematoma,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Internal haemorrhage,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Lactic acidosis,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Peripheral vascular disorder,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Puncture site haemorrhage,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121773401,12177340,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Sepsis syndrome,,2016,Q1,1,I,201412.0,20151230.0,20160314,20160314,EXP,,US-BAYER-2016-002532,BAYER,,86.0,YR,E,F,Y,,,20160314.0,,CN,US,US,2016,Q1,Elderly
121855621,12185562,1,PS,EXENATIDE,EXENATIDE,1,Unknown,,,,,U,,,,,,,,2016,Q1,Exposure during pregnancy,,2016,Q1,1,I,,20090922.0,20160316,20160316,PER,,US-ASTRAZENECA-2009BM00465,ASTRAZENECA,,35.0,YR,,F,Y,160.5,KG,20160316.0,,MD,US,US,2016,Q1,Adult
122160031,12216003,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Decreased appetite,,2016,Q1,1,I,,20080703.0,20160329,20160329,PER,,US-ASTRAZENECA-2008BM09277,ASTRAZENECA,,50.0,YR,,F,Y,,,20160329.0,,,US,US,2016,Q1,Adult
122160031,12216003,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Diarrhoea,,2016,Q1,1,I,,20080703.0,20160329,20160329,PER,,US-ASTRAZENECA-2008BM09277,ASTRAZENECA,,50.0,YR,,F,Y,,,20160329.0,,,US,US,2016,Q1,Adult
122160031,12216003,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Nausea,,2016,Q1,1,I,,20080703.0,20160329,20160329,PER,,US-ASTRAZENECA-2008BM09277,ASTRAZENECA,,50.0,YR,,F,Y,,,20160329.0,,,US,US,2016,Q1,Adult
122160031,12216003,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q1,Weight decreased,,2016,Q1,1,I,,20080703.0,20160329,20160329,PER,,US-ASTRAZENECA-2008BM09277,ASTRAZENECA,,50.0,YR,,F,Y,,,20160329.0,,,US,US,2016,Q1,Adult
71349492,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Amniotic cavity infection,,2016,Q1,2,F,,20160126.0,20090930,20160128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160128.0,,OT,US,US,2016,Q1,Adult
71349492,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Caesarean section,,2016,Q1,2,F,,20160126.0,20090930,20160128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160128.0,,OT,US,US,2016,Q1,Adult
71349492,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Live birth,,2016,Q1,2,F,,20160126.0,20090930,20160128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160128.0,,OT,US,US,2016,Q1,Adult
71349492,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Maternal exposure during pregnancy,,2016,Q1,2,F,,20160126.0,20090930,20160128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160128.0,,OT,US,US,2016,Q1,Adult
71349492,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Pre-eclampsia,,2016,Q1,2,F,,20160126.0,20090930,20160128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160128.0,,OT,US,US,2016,Q1,Adult
71349492,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q1,Urinary tract infection,,2016,Q1,2,F,,20160126.0,20090930,20160128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160128.0,,OT,US,US,2016,Q1,Adult
111977033,11197703,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE WEEKLY,,,,U,,,,,,,,2016,Q2,Thyroid cancer,,2016,Q2,3,F,20150323.0,20160422.0,20150617,20160429,EXP,,US-ASTRAZENECA-2015SE50933,ASTRAZENECA,,21886.0,DY,,M,Y,110.7,KG,20160429.0,,MD,US,US,2016,Q2,Elderly
117744193,11774419,1,PS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Acute kidney injury,,2016,Q2,3,F,20150416.0,20160503.0,20151124,20160511,EXP,,US-ASTRAZENECA-2015SF12186,ASTRAZENECA,,70.0,YR,,M,Y,114.0,KG,20160511.0,,CN,US,US,2016,Q2,Elderly
117744193,11774419,1,PS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Cardiac failure congestive,,2016,Q2,3,F,20150416.0,20160503.0,20151124,20160511,EXP,,US-ASTRAZENECA-2015SF12186,ASTRAZENECA,,70.0,YR,,M,Y,114.0,KG,20160511.0,,CN,US,US,2016,Q2,Elderly
117744193,11774419,1,PS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Cholecystitis acute,,2016,Q2,3,F,20150416.0,20160503.0,20151124,20160511,EXP,,US-ASTRAZENECA-2015SF12186,ASTRAZENECA,,70.0,YR,,M,Y,114.0,KG,20160511.0,,CN,US,US,2016,Q2,Elderly
117744193,11774419,1,PS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Decreased appetite,,2016,Q2,3,F,20150416.0,20160503.0,20151124,20160511,EXP,,US-ASTRAZENECA-2015SF12186,ASTRAZENECA,,70.0,YR,,M,Y,114.0,KG,20160511.0,,CN,US,US,2016,Q2,Elderly
117744193,11774419,1,PS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Pancreatitis acute,,2016,Q2,3,F,20150416.0,20160503.0,20151124,20160511,EXP,,US-ASTRAZENECA-2015SF12186,ASTRAZENECA,,70.0,YR,,M,Y,114.0,KG,20160511.0,,CN,US,US,2016,Q2,Elderly
117762699,11776269,38,C,EXENATIDE,EXENATIDE,1,,"2 MG, UNK",,,,,,,,2.0,MG,,,2016,Q2,Drug effect incomplete,,2016,Q2,9,F,20150821.0,20160525.0,20151125,20160530,EXP,,US-PFIZER INC-2015389542,PFIZER,,73.0,YR,,F,Y,98.0,KG,20160530.0,,MD,US,US,2016,Q2,Elderly
117762699,11776269,38,C,EXENATIDE,EXENATIDE,1,,"2 MG, UNK",,,,,,,,2.0,MG,,,2016,Q2,Lower limb fracture,,2016,Q2,9,F,20150821.0,20160525.0,20151125,20160530,EXP,,US-PFIZER INC-2015389542,PFIZER,,73.0,YR,,F,Y,98.0,KG,20160530.0,,MD,US,US,2016,Q2,Elderly
117762699,11776269,38,C,EXENATIDE,EXENATIDE,1,,"2 MG, UNK",,,,,,,,2.0,MG,,,2016,Q2,Road traffic accident,,2016,Q2,9,F,20150821.0,20160525.0,20151125,20160530,EXP,,US-PFIZER INC-2015389542,PFIZER,,73.0,YR,,F,Y,98.0,KG,20160530.0,,MD,US,US,2016,Q2,Elderly
117762699,11776269,38,C,EXENATIDE,EXENATIDE,1,,"2 MG, UNK",,,,,,,,2.0,MG,,,2016,Q2,Somnolence,,2016,Q2,9,F,20150821.0,20160525.0,20151125,20160530,EXP,,US-PFIZER INC-2015389542,PFIZER,,73.0,YR,,F,Y,98.0,KG,20160530.0,,MD,US,US,2016,Q2,Elderly
118495012,11849501,18,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q2,Cardiac failure congestive,,2016,Q2,2,F,20150416.0,20160502.0,20151218,20160512,EXP,,US-ELI_LILLY_AND_COMPANY-US201512002061,ELI LILLY AND CO,,70.0,YR,,M,Y,117.0,KG,20160512.0,,CN,US,US,2016,Q2,Elderly
118495012,11849501,18,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q2,Cholecystitis acute,,2016,Q2,2,F,20150416.0,20160502.0,20151218,20160512,EXP,,US-ELI_LILLY_AND_COMPANY-US201512002061,ELI LILLY AND CO,,70.0,YR,,M,Y,117.0,KG,20160512.0,,CN,US,US,2016,Q2,Elderly
118495012,11849501,18,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q2,Decreased appetite,,2016,Q2,2,F,20150416.0,20160502.0,20151218,20160512,EXP,,US-ELI_LILLY_AND_COMPANY-US201512002061,ELI LILLY AND CO,,70.0,YR,,M,Y,117.0,KG,20160512.0,,CN,US,US,2016,Q2,Elderly
118495012,11849501,18,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q2,Pancreatitis acute,,2016,Q2,2,F,20150416.0,20160502.0,20151218,20160512,EXP,,US-ELI_LILLY_AND_COMPANY-US201512002061,ELI LILLY AND CO,,70.0,YR,,M,Y,117.0,KG,20160512.0,,CN,US,US,2016,Q2,Elderly
118495012,11849501,18,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q2,Renal failure,,2016,Q2,2,F,20150416.0,20160502.0,20151218,20160512,EXP,,US-ELI_LILLY_AND_COMPANY-US201512002061,ELI LILLY AND CO,,70.0,YR,,M,Y,117.0,KG,20160512.0,,CN,US,US,2016,Q2,Elderly
122305882,12230588,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q2,Gastrointestinal haemorrhage,,2016,Q2,2,F,20140611.0,20160414.0,20160401,20160507,PER,,US-JNJFOC-20160226608,JANSSEN,,83.0,YR,E,M,Y,,,20160507.0,,CN,US,US,2016,Q2,Elderly
122305882,12230588,14,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,UNSPECIFIED,,2016,Q2,Haematuria,,2016,Q2,2,F,20140611.0,20160414.0,20160401,20160507,PER,,US-JNJFOC-20160226608,JANSSEN,,83.0,YR,E,M,Y,,,20160507.0,,CN,US,US,2016,Q2,Elderly
122390861,12239086,4,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Lip swelling,,2016,Q2,1,I,20160316.0,20160330.0,20160405,20160405,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-19891UK",BOEHRINGER INGELHEIM,,65.0,YR,,M,Y,115.0,KG,20160405.0,,OT,GB,GB,2016,Q2,Elderly
122390861,12239086,4,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Pruritus,,2016,Q2,1,I,20160316.0,20160330.0,20160405,20160405,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-19891UK",BOEHRINGER INGELHEIM,,65.0,YR,,M,Y,115.0,KG,20160405.0,,OT,GB,GB,2016,Q2,Elderly
122390861,12239086,4,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Rash erythematous,,2016,Q2,1,I,20160316.0,20160330.0,20160405,20160405,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-19891UK",BOEHRINGER INGELHEIM,,65.0,YR,,M,Y,115.0,KG,20160405.0,,OT,GB,GB,2016,Q2,Elderly
122686431,12268643,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,21773.0,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q2,Blood glucose decreased,,2016,Q2,1,I,200511.0,20051223.0,20160414,20160414,PER,,US-ASTRAZENECA-2005BM05808,ASTRAZENECA,,633.0,MON,,M,Y,99.8,KG,20160414.0,,CN,US,US,2016,Q2,Elderly
122686431,12268643,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,21773.0,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q2,Intentional device misuse,,2016,Q2,1,I,200511.0,20051223.0,20160414,20160414,PER,,US-ASTRAZENECA-2005BM05808,ASTRAZENECA,,633.0,MON,,M,Y,99.8,KG,20160414.0,,CN,US,US,2016,Q2,Elderly
122686431,12268643,2,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,21773.0,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q2,Product quality issue,,2016,Q2,1,I,200511.0,20051223.0,20160414,20160414,PER,,US-ASTRAZENECA-2005BM05808,ASTRAZENECA,,633.0,MON,,M,Y,99.8,KG,20160414.0,,CN,US,US,2016,Q2,Elderly
122865241,12286524,4,C,EXENATIDE,EXENATIDE,1,Sublingual,"5 ?G, BID",2000.41699,UG,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q2,Electrocardiogram change,,2016,Q2,1,I,20160321.0,20160414.0,20160420,20160420,EXP,GB-MHRA-MIDB-A5BE01E5-CD21-4DEF-95EC-5BA0A5D1C0E4,GB-ACTAVIS-2016-08258,ACTAVIS,,69.0,YR,,M,Y,,,20160420.0,,CN,GB,GB,2016,Q2,Elderly
122865241,12286524,4,C,EXENATIDE,EXENATIDE,1,Sublingual,"5 ?G, BID",2000.41699,UG,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q2,Hyperkalaemia,,2016,Q2,1,I,20160321.0,20160414.0,20160420,20160420,EXP,GB-MHRA-MIDB-A5BE01E5-CD21-4DEF-95EC-5BA0A5D1C0E4,GB-ACTAVIS-2016-08258,ACTAVIS,,69.0,YR,,M,Y,,,20160420.0,,CN,GB,GB,2016,Q2,Elderly
122874631,12287463,4,C,EXENATIDE,EXENATIDE,1,,"5 UG, 2X/DAY 5MICROGRAMS/0.02ML SOLUTION FOR INJECTION",,,,,,,,5.0,UG,,BID,2016,Q2,Electrocardiogram change,,2016,Q2,1,I,20160321.0,20160414.0,20160420,20160420,EXP,GB-MHRA-MIDB-A5BE01E5-CD21-4DEF-95EC-5BA0A5D1C0E4,GB-PFIZER INC-2016215471,PFIZER,,69.0,YR,,M,Y,,,20160420.0,,PH,GB,GB,2016,Q2,Elderly
122874631,12287463,4,C,EXENATIDE,EXENATIDE,1,,"5 UG, 2X/DAY 5MICROGRAMS/0.02ML SOLUTION FOR INJECTION",,,,,,,,5.0,UG,,BID,2016,Q2,Hyperkalaemia,,2016,Q2,1,I,20160321.0,20160414.0,20160420,20160420,EXP,GB-MHRA-MIDB-A5BE01E5-CD21-4DEF-95EC-5BA0A5D1C0E4,GB-PFIZER INC-2016215471,PFIZER,,69.0,YR,,M,Y,,,20160420.0,,PH,GB,GB,2016,Q2,Elderly
123079801,12307980,14,C,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q2,Gastrointestinal haemorrhage,,2016,Q2,1,I,20140611.0,20160222.0,20160426,20160426,EXP,,US-BAYER-2016-040551,BAYER,,83.0,YR,E,M,Y,,,20160426.0,,CN,US,US,2016,Q2,Elderly
123079801,12307980,14,C,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q2,Haematuria,,2016,Q2,1,I,20140611.0,20160222.0,20160426,20160426,EXP,,US-BAYER-2016-040551,BAYER,,83.0,YR,E,M,Y,,,20160426.0,,CN,US,US,2016,Q2,Elderly
123169431,12316943,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,,QW,2016,Q2,Injection site mass,,2016,Q2,1,I,20160413.0,,20160428,20160428,DIR,,,,,43.0,YR,,M,N,,,20160427.0,N,PH,US,,2016,Q2,Adult
123256821,12325682,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,,,,,2016,Q2,Peripheral T-cell lymphoma unspecified,,2016,Q2,1,I,20151012.0,20160420.0,20160503,20160503,EXP,,US-ASTRAZENECA-2016SE43449,ASTRAZENECA,,14711.0,DY,,M,Y,97.1,KG,20160503.0,,MD,US,US,2016,Q2,Elderly
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Decreased appetite,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Emotional disorder,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Headache,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Increased tendency to bruise,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Injection site nodule,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Injection site pain,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Nausea,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123280171,12328017,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,POWDER FOR SUSPENSION FOR INJECTION,/wk,2016,Q2,Weight decreased,,2016,Q2,1,I,201111.0,20121023.0,20160503,20160503,PER,,US-ASTRAZENECA-2012BM14231,ASTRAZENECA,,53.0,YR,,F,Y,153.7,KG,20160503.0,,,US,US,2016,Q2,Adult
123436191,12343619,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,8.0,MG,,,,,22200.0,2.0,MG,INJECTION,/wk,2016,Q2,Chronic gastritis,,2016,Q2,1,I,20131018.0,20160428.0,20160506,20160506,EXP,,BG-ASTRAZENECA-2016SE46800,ASTRAZENECA,,68.0,YR,,F,Y,77.0,KG,20160507.0,,MD,BG,BG,2016,Q2,Elderly
123454921,12345492,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q2,Drug dose omission,,2016,Q2,1,I,20160324.0,20120605.0,20160509,20160509,PER,,US-ASTRAZENECA-2012BM09468,ASTRAZENECA,,3615.0,WK,,F,Y,90.7,KG,20160509.0,,CN,US,US,2016,Q2,Elderly
123454921,12345492,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q2,Underdose,,2016,Q2,1,I,20160324.0,20120605.0,20160509,20160509,PER,,US-ASTRAZENECA-2012BM09468,ASTRAZENECA,,3615.0,WK,,F,Y,90.7,KG,20160509.0,,CN,US,US,2016,Q2,Elderly
123454921,12345492,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q2,Weight decreased,,2016,Q2,1,I,20160324.0,20120605.0,20160509,20160509,PER,,US-ASTRAZENECA-2012BM09468,ASTRAZENECA,,3615.0,WK,,F,Y,90.7,KG,20160509.0,,CN,US,US,2016,Q2,Elderly
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Acute kidney injury,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Acute lung injury,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Distributive shock,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Encephalopathy,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Hypoglycaemia,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Intentional overdose,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Lactic acidosis,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Pulmonary hypertension,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Respiratory failure,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123457932,12345793,4,C,EXENATIDE,EXENATIDE,1,,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Right ventricular dysfunction,,2016,Q2,2,F,,20160510.0,20160509,20160524,EXP,,"AU-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK022829",GLENMARK,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY.. BMJ CASE REPORTS. 2015;1-5",44.0,YR,,M,Y,,,20160524.0,,MD,AU,AU,2016,Q2,Adult
123570821,12357082,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Blood glucose increased,,2016,Q2,1,I,,20160429.0,20160511,20160511,EXP,,RU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036375,BRISTOL MYERS SQUIBB,,56.0,YR,,F,Y,,,20160511.0,,OT,RU,RU,2016,Q2,Adult
123570821,12357082,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Cholecystectomy,,2016,Q2,1,I,,20160429.0,20160511,20160511,EXP,,RU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036375,BRISTOL MYERS SQUIBB,,56.0,YR,,F,Y,,,20160511.0,,OT,RU,RU,2016,Q2,Adult
123570821,12357082,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Hypoglycaemia,,2016,Q2,1,I,,20160429.0,20160511,20160511,EXP,,RU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036375,BRISTOL MYERS SQUIBB,,56.0,YR,,F,Y,,,20160511.0,,OT,RU,RU,2016,Q2,Adult
123570821,12357082,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 ?G, BID",,,,,,,,10.0,UG,,BID,2016,Q2,Off label use,,2016,Q2,1,I,,20160429.0,20160511,20160511,EXP,,RU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036375,BRISTOL MYERS SQUIBB,,56.0,YR,,F,Y,,,20160511.0,,OT,RU,RU,2016,Q2,Adult
123846251,12384625,20,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"2 MG, WEEKLY(INJECT 2 MG SUBCUTANEOUSLY ONCE EACH WEEK.)",,,,,,,,2.0,MG,INJECTION,/wk,2016,Q2,Drug effect decreased,,2016,Q2,1,I,,20160509.0,20160519,20160519,PER,,US-PFIZER INC-2016252830,PFIZER,,58.0,YR,,,Y,,,20160519.0,,MD,US,US,2016,Q2,Adult
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Acute kidney injury,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Altered state of consciousness,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Blood bicarbonate decreased,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Blood creatinine increased,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Blood lactic acid increased,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Blood pH decreased,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Blood potassium increased,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Haematuria,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Proteinuria,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Tubulointerstitial nephritis,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124220051,12422005,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,, UNK,,,5.0,UG,,BID,2016,Q2,Vomiting,,2016,Q2,1,I,,20160525.0,20160531,20160531,EXP,,FR-SA-2016SA103722,AVENTIS,"DUBOIS-LAFORGUE D, BOUTBOUL D, LEVY DJ, JOLY D, TIMSIT J.SEVERE ACUTE RENAL FAILURE IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS. DIABETES RESEARCH AND CLINICAL PRACTICE 2014;103:E53-55. AVAILABLE FROM: HTTP://DX.DOI.ORG/10.1016/J.DIABRES.2013.11.014. ACCESSED: 2013 NOV 20.",75.0,YR,E,M,Y,,,20160531.0,,OT,FR,FR,2016,Q2,Elderly
124239132,12423913,7,C,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q2,Gastrointestinal haemorrhage,,2016,Q2,2,F,20140527.0,20160620.0,20160601,20160629,EXP,,US-BAYER-2016-063198,BAYER,,67.0,YR,E,M,Y,,,20160629.0,,OT,US,US,2016,Q2,Elderly
124239132,12423913,7,C,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q2,Haemorrhagic arteriovenous malformation,,2016,Q2,2,F,20140527.0,20160620.0,20160601,20160629,EXP,,US-BAYER-2016-063198,BAYER,,67.0,YR,E,M,Y,,,20160629.0,,OT,US,US,2016,Q2,Elderly
124408962,12440896,2,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,,,,,,,,,2016,Q2,Urticaria,,2016,Q2,2,F,,20160607.0,20160607,20160621,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-040924,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20160621.0,,CN,GB,GB,2016,Q2,Adult
124452991,12445299,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,170.0,UG,,,,,,5.0,UG,INJECTION,BID,2016,Q2,Diabetes mellitus inadequate control,,2016,Q2,1,I,20160429.0,20160530.0,20160607,20160607,EXP,,CN-ASTRAZENECA-2016SE58619,ASTRAZENECA,,49.0,YR,,M,Y,80.0,KG,20160608.0,,MD,CN,CN,2016,Q2,Adult
124502971,12450297,4,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q2,Drug hypersensitivity,,2016,Q2,1,I,,20160602.0,20160609,20160609,PER,,US-PFIZER INC-2016285874,PFIZER,,58.0,YR,,,Y,,,20160609.0,,MD,US,US,2016,Q2,Adult
124998551,12499855,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,Y,D,,,,2.0,MG,,QW,2016,Q2,Injection site haemorrhage,,2016,Q2,1,I,20160425.0,,20160624,20160624,DIR,,,,,52.0,YR,,M,N,156.8,KG,20160622.0,N,PH,US,,2016,Q2,Adult
124998551,12499855,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,Y,D,,,,2.0,MG,,QW,2016,Q2,Injection site nodule,,2016,Q2,1,I,20160425.0,,20160624,20160624,DIR,,,,,52.0,YR,,M,N,156.8,KG,20160622.0,N,PH,US,,2016,Q2,Adult
124998551,12499855,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,Y,D,,,,2.0,MG,,QW,2016,Q2,Injection site pain,,2016,Q2,1,I,20160425.0,,20160624,20160624,DIR,,,,,52.0,YR,,M,N,156.8,KG,20160622.0,N,PH,US,,2016,Q2,Adult
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Death,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Musculoskeletal discomfort,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Oxygen saturation decreased,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Pericardial effusion,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Pleural effusion,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Pulmonary veno-occlusive disease,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
125085741,12508574,15,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q2,Shoulder arthroplasty,,2016,Q2,1,I,20140731.0,20140820.0,20160629,20160629,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160629.0,,OT,US,US,2016,Q2,Elderly
95953592,9595359,3,SS,EXENATIDE,EXENATIDE,1,Unknown,BEFORE A MEAL,,,,,,,,10.0,UG,,BID,2016,Q2,Dyspnoea,,2016,Q2,2,F,201306.0,20131001.0,20131004,20160520,EXP,,US-ROCHE-1284387,ROCHE,,52.0,YR,,M,Y,114.3,KG,20160520.0,,MD,US,US,2016,Q2,Adult
95953592,9595359,3,SS,EXENATIDE,EXENATIDE,1,Unknown,BEFORE A MEAL,,,,,,,,10.0,UG,,BID,2016,Q2,Oesophageal food impaction,,2016,Q2,2,F,201306.0,20131001.0,20131004,20160520,EXP,,US-ROCHE-1284387,ROCHE,,52.0,YR,,M,Y,114.3,KG,20160520.0,,MD,US,US,2016,Q2,Adult
95953592,9595359,4,SS,EXENATIDE,EXENATIDE,1,Unknown,5 MCG/0.02ML SOLUTION,,,,,,,,5.0,UG,,Q12H,2016,Q2,Dyspnoea,,2016,Q2,2,F,201306.0,20131001.0,20131004,20160520,EXP,,US-ROCHE-1284387,ROCHE,,52.0,YR,,M,Y,114.3,KG,20160520.0,,MD,US,US,2016,Q2,Adult
95953592,9595359,4,SS,EXENATIDE,EXENATIDE,1,Unknown,5 MCG/0.02ML SOLUTION,,,,,,,,5.0,UG,,Q12H,2016,Q2,Oesophageal food impaction,,2016,Q2,2,F,201306.0,20131001.0,20131004,20160520,EXP,,US-ROCHE-1284387,ROCHE,,52.0,YR,,M,Y,114.3,KG,20160520.0,,MD,US,US,2016,Q2,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Acute kidney injury,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Anion gap increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Base excess decreased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Blood bicarbonate decreased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Blood creatinine increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Blood lactic acid increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Blood pH decreased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Blood urea increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Blood uric acid increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,C-reactive protein increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Condition aggravated,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Costovertebral angle tenderness,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Decreased appetite,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Dehydration,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Drug level increased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Fatigue,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Hypoglycaemia,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Metabolic acidosis,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Oedema peripheral,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,PO2 decreased,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Peripheral circulatory failure,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
109532305,10953230,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Renal impairment,,2016,Q3,5,F,,20160901.0,20150325,20160907,EXP,,JP-SA-2015SA035905,AVENTIS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233",64.0,YR,A,F,Y,77.2,KG,20160907.0,,MD,JP,JP,2016,Q3,Adult
110061733,11006173,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,Y,,,,22200.0,2.0,MG,,/wk,2016,Q3,Pancreatitis,,2016,Q3,3,F,20130722.0,20160920.0,20150409,20160927,EXP,,US-ASTRAZENECA-2013SE64092,ASTRAZENECA,,61.0,YR,,M,Y,111.6,KG,20160927.0,,CN,US,US,2016,Q3,Adult
114922882,11492288,3,C,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,U,,,,,,,,,2016,Q3,Blood glucose fluctuation,,2016,Q3,2,F,,20160803.0,20150910,20160803,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-034580,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,74.0,KG,20160803.0,,CN,DE,JP,2016,Q3,Adult
114922882,11492288,3,C,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,U,,,,,,,,,2016,Q3,Diabetic retinopathy,,2016,Q3,2,F,,20160803.0,20150910,20160803,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-034580,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,74.0,KG,20160803.0,,CN,DE,JP,2016,Q3,Adult
114922882,11492288,3,C,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,U,,,,,,,,,2016,Q3,Gestational hypertension,,2016,Q3,2,F,,20160803.0,20150910,20160803,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-034580,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,74.0,KG,20160803.0,,CN,DE,JP,2016,Q3,Adult
114922882,11492288,3,C,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,U,,,,,,,,,2016,Q3,Maternal exposure during pregnancy,,2016,Q3,2,F,,20160803.0,20150910,20160803,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-034580,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,74.0,KG,20160803.0,,CN,DE,JP,2016,Q3,Adult
114922882,11492288,3,C,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,U,,,,,,,,,2016,Q3,Normal newborn,,2016,Q3,2,F,,20160803.0,20150910,20160803,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-034580,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,74.0,KG,20160803.0,,CN,DE,JP,2016,Q3,Adult
117051535,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,U,,,,,,,FORMULATION UNKNOWN,,2016,Q3,Acute kidney injury,,2016,Q3,5,F,20150416.0,20160628.0,20151106,20160705,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160705.0,,MD,US,US,2016,Q3,Elderly
117051535,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,U,,,,,,,FORMULATION UNKNOWN,,2016,Q3,Cardiac failure congestive,,2016,Q3,5,F,20150416.0,20160628.0,20151106,20160705,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160705.0,,MD,US,US,2016,Q3,Elderly
117051535,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,U,,,,,,,FORMULATION UNKNOWN,,2016,Q3,Cholecystitis acute,,2016,Q3,5,F,20150416.0,20160628.0,20151106,20160705,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160705.0,,MD,US,US,2016,Q3,Elderly
117051535,11705153,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN FREQ.",,,U,,,,,,,FORMULATION UNKNOWN,,2016,Q3,Pancreatitis acute,,2016,Q3,5,F,20150416.0,20160628.0,20151106,20160705,EXP,,US-ASTELLAS-2015US040202,ASTELLAS,,70.0,YR,,M,Y,114.0,KG,20160705.0,,MD,US,US,2016,Q3,Elderly
117428054,11742805,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNSPECIFIED,,2016,Q3,Acute kidney injury,,2016,Q3,4,F,20150416.0,20160802.0,20151116,20160805,EXP,,US-JNJFOC-20151111509,JANSSEN,,70.0,YR,E,M,Y,114.0,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
117428054,11742805,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNSPECIFIED,,2016,Q3,Cardiac failure congestive,,2016,Q3,4,F,20150416.0,20160802.0,20151116,20160805,EXP,,US-JNJFOC-20151111509,JANSSEN,,70.0,YR,E,M,Y,114.0,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
117428054,11742805,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNSPECIFIED,,2016,Q3,Cholecystitis acute,,2016,Q3,4,F,20150416.0,20160802.0,20151116,20160805,EXP,,US-JNJFOC-20151111509,JANSSEN,,70.0,YR,E,M,Y,114.0,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
117428054,11742805,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNSPECIFIED,,2016,Q3,Pancreatitis acute,,2016,Q3,4,F,20150416.0,20160802.0,20151116,20160805,EXP,,US-JNJFOC-20151111509,JANSSEN,,70.0,YR,E,M,Y,114.0,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
118691473,11869147,17,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,3,F,20150416.0,20160803.0,20151226,20160810,EXP,,US-AMGEN-USASP2015136578,AMGEN,,70.0,YR,E,M,Y,114.0,KG,20160810.0,,CN,US,US,2016,Q3,Elderly
118691473,11869147,17,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q3,Cardiac failure congestive,,2016,Q3,3,F,20150416.0,20160803.0,20151226,20160810,EXP,,US-AMGEN-USASP2015136578,AMGEN,,70.0,YR,E,M,Y,114.0,KG,20160810.0,,CN,US,US,2016,Q3,Elderly
118691473,11869147,17,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q3,Cholecystitis acute,,2016,Q3,3,F,20150416.0,20160803.0,20151226,20160810,EXP,,US-AMGEN-USASP2015136578,AMGEN,,70.0,YR,E,M,Y,114.0,KG,20160810.0,,CN,US,US,2016,Q3,Elderly
118691473,11869147,17,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,,,,,,,,,,2016,Q3,Pancreatitis acute,,2016,Q3,3,F,20150416.0,20160803.0,20151226,20160810,EXP,,US-AMGEN-USASP2015136578,AMGEN,,70.0,YR,E,M,Y,114.0,KG,20160810.0,,CN,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Application site discharge,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Application site dryness,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Application site erythema,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Application site pruritus,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Application site swelling,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Application site vesicles,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Blister,Blister,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Condition aggravated,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Localised infection,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Pain,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Peripheral swelling,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Skin discolouration,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Skin exfoliation,,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Skin ulcer,Skin ulcer,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
119674577,11967457,17,C,EXENATIDE,EXENATIDE,1,,,,,,U,,,,,,,,2016,Q3,Staphylococcal infection,Staphylococcal infection,2016,Q3,7,F,201601.0,20160721.0,20160127,20160802,PER,,"US-ACTELION PHARMACEUTICALS US, INC.-A-NJ2016-130445",ACTELION,,71.0,YR,E,M,Y,,,20160802.0,,OT,US,US,2016,Q3,Elderly
122620803,12262080,19,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,U,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,3,F,20150416.0,20160803.0,20160413,20160812,EXP,,US-GLAXOSMITHKLINE-US2015182086,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160812.0,,OT,US,US,2016,Q3,Elderly
122620803,12262080,19,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,U,,,,,,,,,2016,Q3,Cardiac failure congestive,,2016,Q3,3,F,20150416.0,20160803.0,20160413,20160812,EXP,,US-GLAXOSMITHKLINE-US2015182086,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160812.0,,OT,US,US,2016,Q3,Elderly
122620803,12262080,19,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,U,,,,,,,,,2016,Q3,Cholecystitis acute,,2016,Q3,3,F,20150416.0,20160803.0,20160413,20160812,EXP,,US-GLAXOSMITHKLINE-US2015182086,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160812.0,,OT,US,US,2016,Q3,Elderly
122620803,12262080,19,SS,EXENATIDE,EXENATIDE,1,Unknown,UNK,,,U,,,,,,,,,2016,Q3,Pancreatitis acute,,2016,Q3,3,F,20150416.0,20160803.0,20160413,20160812,EXP,,US-GLAXOSMITHKLINE-US2015182086,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160812.0,,OT,US,US,2016,Q3,Elderly
123256822,12325682,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,,,,,2016,Q3,Peripheral T-cell lymphoma unspecified,,2016,Q3,2,F,20151012.0,20160914.0,20160503,20160921,EXP,,US-ASTRAZENECA-2016SE43449,ASTRAZENECA,,14711.0,DY,,M,Y,97.1,KG,20160921.0,,MD,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Musculoskeletal discomfort,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Oxygen saturation decreased,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Pericardial effusion,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Pleural effusion,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Pulmonary veno-occlusive disease,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Respiratory failure,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125085742,12508574,15,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Shoulder arthroplasty,,2016,Q3,2,F,20140731.0,20160914.0,20160629,20160919,EXP,,US-BAYER-2014-126453,BAYER,,65.0,YR,E,F,Y,72.56,KG,20160919.0,,OT,US,US,2016,Q3,Elderly
125322432,12532243,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,, UNKNOWN,,,,,,,2016,Q3,Abdominal pain,,2016,Q3,2,F,20150416.0,20160901.0,20160706,20160913,EXP,,US-SA-2016SA119182,AVENTIS,,70.0,YR,E,M,Y,114.0,KG,20160913.0,,MD,US,US,2016,Q3,Elderly
125322432,12532243,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,, UNKNOWN,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,2,F,20150416.0,20160901.0,20160706,20160913,EXP,,US-SA-2016SA119182,AVENTIS,,70.0,YR,E,M,Y,114.0,KG,20160913.0,,MD,US,US,2016,Q3,Elderly
125322432,12532243,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,, UNKNOWN,,,,,,,2016,Q3,Cardiac failure congestive,,2016,Q3,2,F,20150416.0,20160901.0,20160706,20160913,EXP,,US-SA-2016SA119182,AVENTIS,,70.0,YR,E,M,Y,114.0,KG,20160913.0,,MD,US,US,2016,Q3,Elderly
125322432,12532243,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,, UNKNOWN,,,,,,,2016,Q3,Cholecystitis acute,,2016,Q3,2,F,20150416.0,20160901.0,20160706,20160913,EXP,,US-SA-2016SA119182,AVENTIS,,70.0,YR,E,M,Y,114.0,KG,20160913.0,,MD,US,US,2016,Q3,Elderly
125322432,12532243,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,, UNKNOWN,,,,,,,2016,Q3,Decreased appetite,,2016,Q3,2,F,20150416.0,20160901.0,20160706,20160913,EXP,,US-SA-2016SA119182,AVENTIS,,70.0,YR,E,M,Y,114.0,KG,20160913.0,,MD,US,US,2016,Q3,Elderly
125322432,12532243,17,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,,, UNKNOWN,,,,,,,2016,Q3,Pancreatitis acute,,2016,Q3,2,F,20150416.0,20160901.0,20160706,20160913,EXP,,US-SA-2016SA119182,AVENTIS,,70.0,YR,E,M,Y,114.0,KG,20160913.0,,MD,US,US,2016,Q3,Elderly
125630021,12563002,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,2007.0,20090123.0,20160715,20160715,PER,,US-ASTRAZENECA-2009BM01555,ASTRAZENECA,,58.0,YR,,F,Y,,,20160715.0,,CN,US,US,2016,Q3,Adult
125630021,12563002,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Injection site bruising,,2016,Q3,1,I,2007.0,20090123.0,20160715,20160715,PER,,US-ASTRAZENECA-2009BM01555,ASTRAZENECA,,58.0,YR,,F,Y,,,20160715.0,,CN,US,US,2016,Q3,Adult
125630021,12563002,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Weight decreased,,2016,Q3,1,I,2007.0,20090123.0,20160715,20160715,PER,,US-ASTRAZENECA-2009BM01555,ASTRAZENECA,,58.0,YR,,F,Y,,,20160715.0,,CN,US,US,2016,Q3,Adult
125687161,12568716,4,C,EXENATIDE (BYDUREON),,2,,,,,,,,,,,,,,2016,Q3,Pancreatitis,,2016,Q3,1,I,20160715.0,,20160718,20160718,DIR,,,,,58.0,YR,,M,N,128.0,KG,20160716.0,N,MD,US,,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Appetite disorder,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Binge eating,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Blood glucose increased,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Drug dose omission,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Fatigue,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Hyperglycaemia,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Incorrect product storage,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Injection site haemorrhage,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Injection site reaction,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Oedema,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125833752,12583375,6,C,EXENATIDE,EXENATIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,,,,,,2016,Q3,Somnolence,,2016,Q3,2,F,201601.0,20160812.0,20160722,20160817,PER,,US-ELI_LILLY_AND_COMPANY-US201607007279,ELI LILLY AND CO,,60.0,YR,,M,Y,,,20160817.0,,CN,US,US,2016,Q3,Adult
125975894,12597589,12,C,Exenatide,EXENATIDE,1,Subcutaneous,300 MILLIGRAM,,,,,,,,1.2,ML,INJECTION,BID,2016,Q3,Rash pruritic,,2016,Q3,4,F,20160808.0,20160909.0,20160726,20160920,EXP,,US-CELGENEUS-USA-2016075140,CELGENE,,57.0,YR,,F,Y,,,20160920.0,,MD,US,US,2016,Q3,Adult
125975894,12597589,12,C,Exenatide,EXENATIDE,1,Subcutaneous,300 MILLIGRAM,,,,,,,,1.2,ML,INJECTION,BID,2016,Q3,Skin discolouration,,2016,Q3,4,F,20160808.0,20160909.0,20160726,20160920,EXP,,US-CELGENEUS-USA-2016075140,CELGENE,,57.0,YR,,F,Y,,,20160920.0,,MD,US,US,2016,Q3,Adult
125975894,12597589,12,C,Exenatide,EXENATIDE,1,Subcutaneous,300 MILLIGRAM,,,,,,,,1.2,ML,INJECTION,BID,2016,Q3,Skin exfoliation,,2016,Q3,4,F,20160808.0,20160909.0,20160726,20160920,EXP,,US-CELGENEUS-USA-2016075140,CELGENE,,57.0,YR,,F,Y,,,20160920.0,,MD,US,US,2016,Q3,Adult
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Diabetes mellitus inadequate control,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Peripheral arterial occlusive disease,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Prostate cancer,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight decreased,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight increased,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Diabetes mellitus inadequate control,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Peripheral arterial occlusive disease,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Prostate cancer,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight decreased,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126088541,12608854,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight increased,,2016,Q3,1,I,200807.0,20091118.0,20160730,20160730,EXP,,US-ASTRAZENECA-2009BM13387,ASTRAZENECA,,806.0,MON,,M,Y,82.6,KG,20160730.0,,,US,US,2016,Q3,Elderly
126193561,12619356,4,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Expired product administered,,2016,Q3,1,I,20160716.0,20160802.0,20160803,20160803,PER,,US-BAYER-2016-150385,BAYER,,75.0,YR,E,F,Y,56.69,KG,20160803.0,,CN,US,US,2016,Q3,Elderly
126193561,12619356,4,C,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Product use issue,,2016,Q3,1,I,20160716.0,20160802.0,20160803,20160803,PER,,US-BAYER-2016-150385,BAYER,,75.0,YR,E,F,Y,56.69,KG,20160803.0,,CN,US,US,2016,Q3,Elderly
126427741,12642774,3,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,2016.0,20110504.0,20160811,20160811,PER,,US-ASTRAZENECA-2011BM07252,ASTRAZENECA,,77.0,YR,,M,Y,72.6,KG,20160811.0,,,US,US,2016,Q3,Elderly
126427741,12642774,3,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Depression,,2016,Q3,1,I,2016.0,20110504.0,20160811,20160811,PER,,US-ASTRAZENECA-2011BM07252,ASTRAZENECA,,77.0,YR,,M,Y,72.6,KG,20160811.0,,,US,US,2016,Q3,Elderly
126427741,12642774,3,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2016.0,20110504.0,20160811,20160811,PER,,US-ASTRAZENECA-2011BM07252,ASTRAZENECA,,77.0,YR,,M,Y,72.6,KG,20160811.0,,,US,US,2016,Q3,Elderly
126427741,12642774,3,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Memory impairment,,2016,Q3,1,I,2016.0,20110504.0,20160811,20160811,PER,,US-ASTRAZENECA-2011BM07252,ASTRAZENECA,,77.0,YR,,M,Y,72.6,KG,20160811.0,,,US,US,2016,Q3,Elderly
126427741,12642774,3,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,2016.0,20110504.0,20160811,20160811,PER,,US-ASTRAZENECA-2011BM07252,ASTRAZENECA,,77.0,YR,,M,Y,72.6,KG,20160811.0,,,US,US,2016,Q3,Elderly
126427741,12642774,3,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Visual acuity reduced,,2016,Q3,1,I,2016.0,20110504.0,20160811,20160811,PER,,US-ASTRAZENECA-2011BM07252,ASTRAZENECA,,77.0,YR,,M,Y,72.6,KG,20160811.0,,,US,US,2016,Q3,Elderly
126491401,12649140,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,20150416.0,20160808.0,20160812,20160812,EXP,,US-ELI_LILLY_AND_COMPANY-US201608004937,ELI LILLY AND CO,,70.0,YR,,M,Y,114.0,KG,20160812.0,,CN,US,US,2016,Q3,Elderly
126491401,12649140,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q3,Cardiac failure congestive,,2016,Q3,1,I,20150416.0,20160808.0,20160812,20160812,EXP,,US-ELI_LILLY_AND_COMPANY-US201608004937,ELI LILLY AND CO,,70.0,YR,,M,Y,114.0,KG,20160812.0,,CN,US,US,2016,Q3,Elderly
126491401,12649140,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q3,Cholecystitis acute,,2016,Q3,1,I,20150416.0,20160808.0,20160812,20160812,EXP,,US-ELI_LILLY_AND_COMPANY-US201608004937,ELI LILLY AND CO,,70.0,YR,,M,Y,114.0,KG,20160812.0,,CN,US,US,2016,Q3,Elderly
126491401,12649140,18,SS,EXENATIDE,EXENATIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2016,Q3,Pancreatitis acute,,2016,Q3,1,I,20150416.0,20160808.0,20160812,20160812,EXP,,US-ELI_LILLY_AND_COMPANY-US201608004937,ELI LILLY AND CO,,70.0,YR,,M,Y,114.0,KG,20160812.0,,CN,US,US,2016,Q3,Elderly
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Abdominal pain,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Dehydration,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Hypotonia,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Lethargy,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Nausea,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Skin turgor decreased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Tongue dry,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Vomiting,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Weight decreased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Weight increased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Abdominal pain,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Dehydration,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Hypotonia,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Lethargy,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Nausea,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Skin turgor decreased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Tongue dry,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Vomiting,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Weight decreased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Weight increased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Abdominal pain,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Dehydration,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Hypotonia,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Lethargy,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Nausea,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Skin turgor decreased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Tongue dry,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Vomiting,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Weight decreased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126498961,12649896,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,Y,,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Weight increased,,2016,Q3,1,I,,20130925.0,20160812,20160812,EXP,,US-ASTRAZENECA-2013SE86657,ASTRAZENECA,,59.0,YR,,F,Y,86.0,KG,20160813.0,,CN,TR,TR,2016,Q3,Adult
126548411,12654841,18,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Abdominal pain,,2016,Q3,1,I,20150416.0,20160809.0,20160816,20160816,EXP,,US-GLAXOSMITHKLINE-US2016GSK115987,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160816.0,,CN,US,US,2016,Q3,Elderly
126548411,12654841,18,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,20150416.0,20160809.0,20160816,20160816,EXP,,US-GLAXOSMITHKLINE-US2016GSK115987,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160816.0,,CN,US,US,2016,Q3,Elderly
126548411,12654841,18,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Cardiac failure congestive,,2016,Q3,1,I,20150416.0,20160809.0,20160816,20160816,EXP,,US-GLAXOSMITHKLINE-US2016GSK115987,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160816.0,,CN,US,US,2016,Q3,Elderly
126548411,12654841,18,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Cholecystitis acute,,2016,Q3,1,I,20150416.0,20160809.0,20160816,20160816,EXP,,US-GLAXOSMITHKLINE-US2016GSK115987,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160816.0,,CN,US,US,2016,Q3,Elderly
126548411,12654841,18,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Decreased appetite,,2016,Q3,1,I,20150416.0,20160809.0,20160816,20160816,EXP,,US-GLAXOSMITHKLINE-US2016GSK115987,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160816.0,,CN,US,US,2016,Q3,Elderly
126548411,12654841,18,SS,EXENATIDE,EXENATIDE,1,,UNK,,,,,,,,,,,,2016,Q3,Pancreatitis acute,,2016,Q3,1,I,20150416.0,20160809.0,20160816,20160816,EXP,,US-GLAXOSMITHKLINE-US2016GSK115987,GLAXOSMITHKLINE,,70.0,YR,,M,Y,114.0,KG,20160816.0,,CN,US,US,2016,Q3,Elderly
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Cardiopulmonary failure,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Distributive shock,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Encephalopathy,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Intentional overdose,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Metabolic acidosis,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Pulmonary hypertension,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126555131,12655513,5,C,EXENATIDE,EXENATIDE,1,Unknown,"10 MG, 2 /DAY",,,,,,,,10.0,MG,,BID,2016,Q3,Tachyarrhythmia,,2016,Q3,1,I,,20150819.0,20160816,20160816,EXP,,"AU-IMPAX LABORATORIES, INC-2015-IPXL-00881",IMPAX,"GRAHAM RE, CARTNER M, WINEARLS J.. A SEVERE CASE OF VASOPLEGIC SHOCK FOLLOWING METFORMIN OVERDOSE SUCCESSFULLY TREATED WITH METHYLENE BLUE AS A LAST LINE THERAPY. BMJ CASE REPORTS. 2015",44.0,YR,,M,Y,,,20160816.0,,OT,AU,AU,2016,Q3,Adult
126584761,12658476,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,20150416.0,20151111.0,20160817,20160817,EXP,,US-ENDO PHARMACEUTICALS INC.-2015-004271,ENDO,,70.0,YR,,M,Y,114.0,KG,20160817.0,,,COUNTRY NOT SPECIFIED,US,2016,Q3,Elderly
126584761,12658476,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2016,Q3,Cardiac failure congestive,,2016,Q3,1,I,20150416.0,20151111.0,20160817,20160817,EXP,,US-ENDO PHARMACEUTICALS INC.-2015-004271,ENDO,,70.0,YR,,M,Y,114.0,KG,20160817.0,,,COUNTRY NOT SPECIFIED,US,2016,Q3,Elderly
126584761,12658476,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2016,Q3,Cholecystitis acute,,2016,Q3,1,I,20150416.0,20151111.0,20160817,20160817,EXP,,US-ENDO PHARMACEUTICALS INC.-2015-004271,ENDO,,70.0,YR,,M,Y,114.0,KG,20160817.0,,,COUNTRY NOT SPECIFIED,US,2016,Q3,Elderly
126584761,12658476,18,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2016,Q3,Pancreatitis acute,,2016,Q3,1,I,20150416.0,20151111.0,20160817,20160817,EXP,,US-ENDO PHARMACEUTICALS INC.-2015-004271,ENDO,,70.0,YR,,M,Y,114.0,KG,20160817.0,,,COUNTRY NOT SPECIFIED,US,2016,Q3,Elderly
126600442,12660044,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,4238.0,UG,,,,,21773.0,1.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Cholangiocarcinoma,,2016,Q3,2,F,20141229.0,20160829.0,20160817,20160906,EXP,,GB-ASTRAZENECA-2016SE86372,ASTRAZENECA,,55.0,YR,,M,Y,112.0,KG,20160906.0,,MD,GB,GB,2016,Q3,Adult
126600442,12660044,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,4238.0,UG,,,,,21773.0,1.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Pancreatic carcinoma,,2016,Q3,2,F,20141229.0,20160829.0,20160817,20160906,EXP,,GB-ASTRAZENECA-2016SE86372,ASTRAZENECA,,55.0,YR,,M,Y,112.0,KG,20160906.0,,MD,GB,GB,2016,Q3,Adult
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Abdominal mass,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Intentional product misuse,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Localised infection,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Lymphoedema,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Nausea,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Needle issue,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Neuropathy peripheral,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Pain in extremity,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Peripheral swelling,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126603122,12660312,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Sepsis,,2016,Q3,2,F,201201.0,20160916.0,20160817,20160922,EXP,,US-ASTRAZENECA-2010BM06379,ASTRAZENECA,,642.0,MON,,F,Y,120.2,KG,20160922.0,,,US,US,2016,Q3,Elderly
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Decreased appetite,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Drug level increased,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Hypoglycaemia,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Peripheral circulatory failure,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126780901,12678090,4,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,,,,,,20.0,UG,,QD,2016,Q3,Urinary tract infection,,2016,Q3,1,I,,20160810.0,20160823,20160823,EXP,,"JP-IMPAX LABORATORIES, INC-2016-IPXL-00912",IMPAX,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y,  UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE + SURGERY.. 2016",64.0,YR,,F,Y,77.0,KG,20160823.0,,OT,JP,JP,2016,Q3,Adult
126802743,12680274,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,U,U,,,,20.0,UG,,,2016,Q3,Condition aggravated,,2016,Q3,3,F,,20160826.0,20160824,20160907,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-122510,RANBAXY,,64.0,YR,,F,Y,77.2,KG,20160907.0,,OT,GB,JP,2016,Q3,Adult
126802743,12680274,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,U,U,,,,20.0,UG,,,2016,Q3,Hypoglycaemia,,2016,Q3,3,F,,20160826.0,20160824,20160907,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-122510,RANBAXY,,64.0,YR,,F,Y,77.2,KG,20160907.0,,OT,GB,JP,2016,Q3,Adult
126802743,12680274,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,U,U,,,,20.0,UG,,,2016,Q3,Lactic acidosis,,2016,Q3,3,F,,20160826.0,20160824,20160907,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-122510,RANBAXY,,64.0,YR,,F,Y,77.2,KG,20160907.0,,OT,GB,JP,2016,Q3,Adult
126802743,12680274,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, DAILY",,,U,U,,,,20.0,UG,,,2016,Q3,Renal impairment,,2016,Q3,3,F,,20160826.0,20160824,20160907,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-122510,RANBAXY,,64.0,YR,,F,Y,77.2,KG,20160907.0,,OT,GB,JP,2016,Q3,Adult
126817682,12681768,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Condition aggravated,,2016,Q3,2,F,,20160817.0,20160824,20160830,EXP,,JP-BAUSCH-BL-2016-020034,BAUSCH AND LOMB,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016;.",64.0,YR,,F,Y,77.2,KG,20160830.0,,MD,JP,JP,2016,Q3,Adult
126817682,12681768,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Hypoglycaemia,,2016,Q3,2,F,,20160817.0,20160824,20160830,EXP,,JP-BAUSCH-BL-2016-020034,BAUSCH AND LOMB,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016;.",64.0,YR,,F,Y,77.2,KG,20160830.0,,MD,JP,JP,2016,Q3,Adult
126817682,12681768,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,2,F,,20160817.0,20160824,20160830,EXP,,JP-BAUSCH-BL-2016-020034,BAUSCH AND LOMB,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016;.",64.0,YR,,F,Y,77.2,KG,20160830.0,,MD,JP,JP,2016,Q3,Adult
126817682,12681768,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,QD,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160817.0,20160824,20160830,EXP,,JP-BAUSCH-BL-2016-020034,BAUSCH AND LOMB,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016;.",64.0,YR,,F,Y,77.2,KG,20160830.0,,MD,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Acid base balance abnormal,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Anorectal disorder,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Escherichia urinary tract infection,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Fatigue,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Hypoglycaemia,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Oedema peripheral,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Pyrexia,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126846591,12684659,7,C,EXENATIDE,EXENATIDE,1,Unknown,"20 IG, , QD",,,U,,,,,,,,QD,2016,Q3,Renal impairment,,2016,Q3,1,I,,20160818.0,20160825,20160825,EXP,,PHHY2016JP113742,SANDOZ,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160825.0,,OT,JP,JP,2016,Q3,Adult
126876142,12687614,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, OD",,,,,,,,20.0,UG,,QD,2016,Q3,Condition aggravated,,2016,Q3,2,F,,20160824.0,20160826,20160831,EXP,JP-MLMSERVICE-20160811-0388597-1,"JP-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK024028",GLENMARK,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL.. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK.. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160831.0,,MD,JP,JP,2016,Q3,Adult
126876142,12687614,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, OD",,,,,,,,20.0,UG,,QD,2016,Q3,Hypoglycaemia,,2016,Q3,2,F,,20160824.0,20160826,20160831,EXP,JP-MLMSERVICE-20160811-0388597-1,"JP-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK024028",GLENMARK,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL.. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK.. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160831.0,,MD,JP,JP,2016,Q3,Adult
126876142,12687614,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, OD",,,,,,,,20.0,UG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,2,F,,20160824.0,20160826,20160831,EXP,JP-MLMSERVICE-20160811-0388597-1,"JP-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK024028",GLENMARK,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL.. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK.. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160831.0,,MD,JP,JP,2016,Q3,Adult
126876142,12687614,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, OD",,,,,,,,20.0,UG,,QD,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160824.0,20160826,20160831,EXP,JP-MLMSERVICE-20160811-0388597-1,"JP-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK024028",GLENMARK,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL.. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK.. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160831.0,,MD,JP,JP,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Confusional state,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Diarrhoea,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Intentional device misuse,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Product quality issue,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126925301,12692530,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Underdose,,2016,Q3,1,I,200706.0,20071022.0,20160829,20160829,PER,,US-ASTRAZENECA-2007BM17777,ASTRAZENECA,,58.0,YR,,F,Y,99.8,KG,20160829.0,,,US,US,2016,Q3,Adult
126988001,12698800,12,C,EXENATIDE,EXENATIDE,1,,TWICE DAILY,,,,,,,,10.0,UG,,,2016,Q3,Exostosis,,2016,Q3,1,I,20080415.0,20080523.0,20160830,20160830,EXP,,US-PFIZER INC-2008044158,PFIZER,,45.0,YR,,M,Y,101.15,KG,20160830.0,,MD,US,US,2016,Q3,Adult
126988001,12698800,12,C,EXENATIDE,EXENATIDE,1,,TWICE DAILY,,,,,,,,10.0,UG,,,2016,Q3,Myocardial infarction,,2016,Q3,1,I,20080415.0,20080523.0,20160830,20160830,EXP,,US-PFIZER INC-2008044158,PFIZER,,45.0,YR,,M,Y,101.15,KG,20160830.0,,MD,US,US,2016,Q3,Adult
127040832,12704083,7,C,EXENATIDE,EXENATIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2016,Q3,Cerebrovascular accident,,2016,Q3,2,F,20160822.0,20160921.0,20160831,20160923,EXP,,US-JNJFOC-20160820077,JANSSEN,,64.0,YR,A,M,Y,,,20160923.0,,MD,US,US,2016,Q3,Adult
127040832,12704083,7,C,EXENATIDE,EXENATIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2016,Q3,Treatment noncompliance,,2016,Q3,2,F,20160822.0,20160921.0,20160831,20160923,EXP,,US-JNJFOC-20160820077,JANSSEN,,64.0,YR,A,M,Y,,,20160923.0,,MD,US,US,2016,Q3,Adult
127051712,12705171,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,96.0,MG,,,,,,2.0,MG,,/wk,2016,Q3,Loss of consciousness,,2016,Q3,2,F,20160815.0,20160902.0,20160831,20160909,EXP,,CN-ASTRAZENECA-2016SE91067,ASTRAZENECA,,23440.0,DY,,F,Y,89.0,KG,20160909.0,,MD,CN,CN,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Asthenia,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Decreased appetite,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Hot flush,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Malaise,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Nausea,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Tremor,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Vomiting,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059431,12705943,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight decreased,,2016,Q3,1,I,200907.0,20090914.0,20160901,20160901,PER,,US-ASTRAZENECA-2009BM10865,ASTRAZENECA,,790.0,MON,,F,Y,,,20160901.0,,,US,US,2016,Q3,Elderly
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Decreased appetite,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Dehydration,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Escherichia urinary tract infection,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Fatigue,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Hypoglycaemia,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Lactic acidosis,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Leukocytosis,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Peripheral circulatory failure,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127059702,12705970,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Urinary tract infection,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INDICUS PHARMA-000445,INDICUS,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127060231,12706023,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Hypoglycaemia,,2016,Q3,1,I,,20160817.0,20160901,20160901,EXP,,JP-ACCORD-043718,ACCORD,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160901.0,,MD,JP,JP,2016,Q3,Adult
127060231,12706023,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160817.0,20160901,20160901,EXP,,JP-ACCORD-043718,ACCORD,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160901.0,,MD,JP,JP,2016,Q3,Adult
127060231,12706023,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Peripheral circulatory failure,,2016,Q3,1,I,,20160817.0,20160901,20160901,EXP,,JP-ACCORD-043718,ACCORD,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160901.0,,MD,JP,JP,2016,Q3,Adult
127060231,12706023,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Renal impairment,,2016,Q3,1,I,,20160817.0,20160901,20160901,EXP,,JP-ACCORD-043718,ACCORD,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160901.0,,MD,JP,JP,2016,Q3,Adult
127060231,12706023,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Urinary tract infection,,2016,Q3,1,I,,20160817.0,20160901,20160901,EXP,,JP-ACCORD-043718,ACCORD,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160901.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Dehydration,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Escherichia urinary tract infection,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Hypoglycaemia,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Lactic acidosis,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Peripheral circulatory failure,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062762,12706276,6,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,20.0,UG,,,2016,Q3,Urinary tract infection,,2016,Q3,2,F,,20160824.0,20160901,20160906,EXP,JP-MLMSERVICE-20160811-0388597-1,JP-INVENTIA-000133,INVENTIA HEALTHCARE,"NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016",64.0,YR,,F,Y,77.2,KG,20160906.0,,MD,JP,JP,2016,Q3,Adult
127062811,12706281,5,C,EXENATIDE,EXENATIDE,1,,10UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Chest pain,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,5,C,EXENATIDE,EXENATIDE,1,,10UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,5,C,EXENATIDE,EXENATIDE,1,,10UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Myocardial infarction,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,5,C,EXENATIDE,EXENATIDE,1,,10UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Pancreatitis,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,5,C,EXENATIDE,EXENATIDE,1,,10UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Reflux gastritis,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,5,C,EXENATIDE,EXENATIDE,1,,10UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Sinusitis,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,6,C,EXENATIDE,EXENATIDE,1,,5UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Chest pain,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,6,C,EXENATIDE,EXENATIDE,1,,5UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,6,C,EXENATIDE,EXENATIDE,1,,5UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Myocardial infarction,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,6,C,EXENATIDE,EXENATIDE,1,,5UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Pancreatitis,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,6,C,EXENATIDE,EXENATIDE,1,,5UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Reflux gastritis,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127062811,12706281,6,C,EXENATIDE,EXENATIDE,1,,5UG,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Sinusitis,,2016,Q3,1,I,200903.0,20090409.0,20160901,20160901,EXP,,US-ASTRAZENECA-2009BM04704,ASTRAZENECA,,57.0,YR,,F,Y,118.4,KG,20160901.0,,CN,US,US,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Condition aggravated,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Dehydration,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Drug level increased,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Haemodialysis,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Hypoglycaemia,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Peripheral circulatory failure,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Renal injury,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127074612,12707461,6,C,EXENATIDE,EXENATIDE,1,Unknown,"20 ?G, QD",,,U,,,,,20.0,UG,,QD,2016,Q3,Urinary tract infection,,2016,Q3,2,F,,20160829.0,20160901,20160912,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068496,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,77.2,KG,20160912.0,,CN,GB,JP,2016,Q3,Adult
127442831,12744283,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2008.0,20080320.0,20160914,20160914,PER,,US-ASTRAZENECA-2008BM04417,ASTRAZENECA,,46.0,YR,,F,Y,,,20160915.0,,CN,US,US,2016,Q3,Adult
127442831,12744283,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site erythema,,2016,Q3,1,I,2008.0,20080320.0,20160914,20160914,PER,,US-ASTRAZENECA-2008BM04417,ASTRAZENECA,,46.0,YR,,F,Y,,,20160915.0,,CN,US,US,2016,Q3,Adult
127442831,12744283,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site extravasation,,2016,Q3,1,I,2008.0,20080320.0,20160914,20160914,PER,,US-ASTRAZENECA-2008BM04417,ASTRAZENECA,,46.0,YR,,F,Y,,,20160915.0,,CN,US,US,2016,Q3,Adult
127442831,12744283,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site pruritus,,2016,Q3,1,I,2008.0,20080320.0,20160914,20160914,PER,,US-ASTRAZENECA-2008BM04417,ASTRAZENECA,,46.0,YR,,F,Y,,,20160915.0,,CN,US,US,2016,Q3,Adult
127442831,12744283,3,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site urticaria,,2016,Q3,1,I,2008.0,20080320.0,20160914,20160914,PER,,US-ASTRAZENECA-2008BM04417,ASTRAZENECA,,46.0,YR,,F,Y,,,20160915.0,,CN,US,US,2016,Q3,Adult
127547801,12754780,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site nodule,,2016,Q3,1,I,20080706.0,20080707.0,20160915,20160915,PER,,US-ASTRAZENECA-2008BM09348,ASTRAZENECA,,21118.0,DY,,F,Y,,,20160916.0,,,US,US,2016,Q3,Elderly
127547801,12754780,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Oropharyngeal pain,,2016,Q3,1,I,20080706.0,20080707.0,20160915,20160915,PER,,US-ASTRAZENECA-2008BM09348,ASTRAZENECA,,21118.0,DY,,F,Y,,,20160916.0,,,US,US,2016,Q3,Elderly
127547801,12754780,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Palatal disorder,,2016,Q3,1,I,20080706.0,20080707.0,20160915,20160915,PER,,US-ASTRAZENECA-2008BM09348,ASTRAZENECA,,21118.0,DY,,F,Y,,,20160916.0,,,US,US,2016,Q3,Elderly
127547801,12754780,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Product quality issue,,2016,Q3,1,I,20080706.0,20080707.0,20160915,20160915,PER,,US-ASTRAZENECA-2008BM09348,ASTRAZENECA,,21118.0,DY,,F,Y,,,20160916.0,,,US,US,2016,Q3,Elderly
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Decreased appetite,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Glycosylated haemoglobin increased,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Limb injury,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Oedema,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Skin abrasion,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Skin discolouration,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127572491,12757249,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q3,Weight fluctuation,,2016,Q3,1,I,2006.0,20080929.0,20160919,20160919,PER,,US-ASTRAZENECA-2008BM13865,ASTRAZENECA,,36.0,YR,,F,Y,99.8,KG,20160919.0,,CN,US,US,2016,Q3,Adult
127601711,12760171,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"5 ???G, BID",,,,, A254098,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"5 ???G, BID",,,,, A254098,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Blood glucose increased,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"5 ???G, BID",,,,, A254098,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Impaired healing,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,3,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"5 ???G, BID",,,,, A254098,,,5.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Prostatic pain,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 ???G, BID",,,,, A254098,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 ???G, BID",,,,, A254098,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Blood glucose increased,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 ???G, BID",,,,, A254098,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Impaired healing,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127601711,12760171,4,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 ???G, BID",,,,, A254098,,,10.0,UG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,BID,2016,Q3,Prostatic pain,,2016,Q3,1,I,201605.0,20070313.0,20160919,20160919,PER,,US-ASTRAZENECA-2007BM05652,ASTRAZENECA,,688.0,MON,,M,Y,88.5,KG,20160919.0,,CN,US,US,2016,Q3,Elderly
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose abnormal,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Fatigue,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Headache,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Migraine,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Nausea,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Palpitations,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Vomiting,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,5,C,EXENATIDE,EXENATIDE,1,,5 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight decreased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose abnormal,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Fatigue,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Headache,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Migraine,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Nausea,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Palpitations,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Vomiting,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,6,C,EXENATIDE,EXENATIDE,1,,10 MCG PEN,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight decreased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose abnormal,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose decreased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Blood glucose increased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Fatigue,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Headache,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Migraine,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Nausea,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Palpitations,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Vomiting,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127836871,12783687,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Weight decreased,,2016,Q3,1,I,2008.0,20090730.0,20160927,20160927,PER,,US-ASTRAZENECA-2009BM09183,ASTRAZENECA,,61.0,YR,,F,Y,,,20160927.0,,,US,US,2016,Q3,Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Contusion,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Drug administration error,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site haemorrhage,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Injection site swelling,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Off label use,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Pain,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
127970721,12797072,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q3,Product quality issue,,2016,Q3,1,I,2008.0,20100330.0,20160929,20160929,PER,,US-ASTRAZENECA-2010BM04665,ASTRAZENECA,,34.0,YR,,F,Y,48.5,KG,20160929.0,,CN,US,US,2016,Q3,Young Adult
71349493,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,Y,,,,,,,,,2016,Q3,Amniotic cavity infection,,2016,Q3,3,F,,20160824.0,20090930,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160824.0,,OT,US,US,2016,Q3,Adult
71349493,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,Y,,,,,,,,,2016,Q3,Caesarean section,,2016,Q3,3,F,,20160824.0,20090930,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160824.0,,OT,US,US,2016,Q3,Adult
71349493,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,Y,,,,,,,,,2016,Q3,Live birth,,2016,Q3,3,F,,20160824.0,20090930,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160824.0,,OT,US,US,2016,Q3,Adult
71349493,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,Y,,,,,,,,,2016,Q3,Maternal exposure during pregnancy,,2016,Q3,3,F,,20160824.0,20090930,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160824.0,,OT,US,US,2016,Q3,Adult
71349493,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,Y,,,,,,,,,2016,Q3,Pre-eclampsia,,2016,Q3,3,F,,20160824.0,20090930,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160824.0,,OT,US,US,2016,Q3,Adult
71349493,7134949,5,SS,EXENATIDE,EXENATIDE,1,Unknown,,,,Y,,,,,,,,,2016,Q3,Urinary tract infection,,2016,Q3,3,F,,20160824.0,20090930,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14790364,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,160.54,KG,20160824.0,,OT,US,US,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Abdominal pain,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Acute kidney injury,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Dehydration,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Hypotonia,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Lethargy,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Nausea,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Skin turgor decreased,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Tongue dry,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Vomiting,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Weight decreased,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
97087753,9708775,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,"20 MCG (10 MCG,2 IN 1 D)",,,,,,,,5.0,UG,SOLUTION FOR INJECTION,BID,2016,Q3,Weight increased,,2016,Q3,3,F,,20160712.0,20131125,20160712,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19829878,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,86.0,KG,20160712.0,,CN,DE,TR,2016,Q3,Adult
108748116,10874811,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Chronic gastritis,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Duodenitis haemorrhagic,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Gastrooesophageal reflux disease,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Hiatus hernia,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Chronic gastritis,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Duodenitis haemorrhagic,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Gastrooesophageal reflux disease,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
108748116,10874811,2,SS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,,,Y,U,,,22200.0,,,,,2016,Q4,Hiatus hernia,,2016,Q4,6,F,20141209.0,20161026.0,20150227,20161105,EXP,,BG-ASTRAZENECA-2015SE17310,ASTRAZENECA,,72.0,YR,,M,Y,88.0,KG,20161105.0,,MD,BG,BG,2016,Q4,Elderly
113217532,11321753,8,C,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,20.0,UG,,QD,2016,Q4,Urosepsis,,2016,Q4,2,F,20141203.0,20161019.0,20150729,20161025,EXP,,US-ASTRAZENECA-2015SE00319,ASTRAZENECA,,71.0,YR,,M,Y,,,20161025.0,,CN,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Asthma,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Blood glucose increased,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Drug dose omission,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Feeling abnormal,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Intentional product misuse,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Malaise,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
113973733,11397373,8,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,INJECTION,,2016,Q4,Weight decreased,,2016,Q4,3,F,20150807.0,20161117.0,20150819,20161209,PER,,US-ASTRAZENECA-2010BM07596,ASTRAZENECA,,23991.0,DY,,F,Y,131.1,KG,20161209.0,,,US,US,2016,Q4,Elderly
116972524,11697252,13,C,EXENATIDE,EXENATIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2016,Q4,Haemorrhoidal haemorrhage,,2016,Q4,4,F,201310.0,20161220.0,20151104,20161227,EXP,,US-JNJFOC-20151024507,JANSSEN,,63.0,YR,A,F,Y,,,20161227.0,,CN,US,US,2016,Q4,Adult
117243113,11724311,13,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"2 MG, WEEKLY (INJECT 2 MG BENEATH THE SKIN EVERY 7 DAYS)",,,,,,,,2.0,MG,,/wk,2016,Q4,Accident at work,,2016,Q4,3,F,,20161208.0,20151111,20161220,EXP,,US-PFIZER INC-2015380295,PFIZER,,61.0,YR,,M,Y,,,20161220.0,,MD,US,US,2016,Q4,Adult
117243113,11724311,13,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"2 MG, WEEKLY (INJECT 2 MG BENEATH THE SKIN EVERY 7 DAYS)",,,,,,,,2.0,MG,,/wk,2016,Q4,Arthritis,,2016,Q4,3,F,,20161208.0,20151111,20161220,EXP,,US-PFIZER INC-2015380295,PFIZER,,61.0,YR,,M,Y,,,20161220.0,,MD,US,US,2016,Q4,Adult
117243113,11724311,13,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"2 MG, WEEKLY (INJECT 2 MG BENEATH THE SKIN EVERY 7 DAYS)",,,,,,,,2.0,MG,,/wk,2016,Q4,Diabetes mellitus,,2016,Q4,3,F,,20161208.0,20151111,20161220,EXP,,US-PFIZER INC-2015380295,PFIZER,,61.0,YR,,M,Y,,,20161220.0,,MD,US,US,2016,Q4,Adult
123256823,12325682,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,22200.0,,,,,2016,Q4,Peripheral T-cell lymphoma unspecified,,2016,Q4,3,F,20151012.0,20161114.0,20160503,20161121,EXP,,US-ASTRAZENECA-2016SE43449,ASTRAZENECA,,14711.0,DY,,M,Y,97.1,KG,20161121.0,,MD,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Blood glucose increased,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Chills,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Decreased appetite,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Diarrhoea,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Glycosylated haemoglobin increased,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Headache,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Nausea,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Vomiting,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128014511,12801451,4,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Weight decreased,,2016,Q4,1,I,200804.0,20080516.0,20161003,20161003,PER,,US-ASTRAZENECA-2008BM07086,ASTRAZENECA,,20432.0,DY,,F,Y,62.6,KG,20161003.0,,,US,US,2016,Q4,Elderly
128073861,12807386,6,C,EXENATIDE,EXENATIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,US-JNJFOC-20160929806,JANSSEN,"TURNER J, BEGUM T, SMALLIGAN RD. CANAGLIFLOZIN-INDUCED DIABETIC KETOACIDOSIS: CASE REPORT AND REVIEW OF THE LITERATURE. JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS JUL-2016;4(3):1-3.",62.0,YR,A,F,Y,,,20161004.0,,OT,US,US,2016,Q4,Adult
128229771,12822977,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Fatigue,,2016,Q4,1,I,2007.0,20071012.0,20161007,20161007,PER,,US-ASTRAZENECA-2007BM17133,ASTRAZENECA,,25969.0,DY,,F,Y,,,20161007.0,,CN,US,US,2016,Q4,Elderly
128229771,12822977,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Injection site pain,,2016,Q4,1,I,2007.0,20071012.0,20161007,20161007,PER,,US-ASTRAZENECA-2007BM17133,ASTRAZENECA,,25969.0,DY,,F,Y,,,20161007.0,,CN,US,US,2016,Q4,Elderly
128229771,12822977,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Loss of consciousness,,2016,Q4,1,I,2007.0,20071012.0,20161007,20161007,PER,,US-ASTRAZENECA-2007BM17133,ASTRAZENECA,,25969.0,DY,,F,Y,,,20161007.0,,CN,US,US,2016,Q4,Elderly
128229771,12822977,4,C,EXENATIDE,EXENATIDE,1,,"10MCG PEN, DISPOSABLE DEVICE",,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Nausea,,2016,Q4,1,I,2007.0,20071012.0,20161007,20161007,PER,,US-ASTRAZENECA-2007BM17133,ASTRAZENECA,,25969.0,DY,,F,Y,,,20161007.0,,CN,US,US,2016,Q4,Elderly
128400301,12840030,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,14.0,DF,Y,U,,,22200.0,1.0,DF,,/wk,2016,Q4,Acute kidney injury,,2016,Q4,1,I,20160916.0,20161006.0,20161012,20161012,EXP,,DE-ASTRAZENECA-2016SF06849,ASTRAZENECA,,65.0,YR,,F,Y,96.0,KG,20161012.0,,,DE,DE,2016,Q4,Elderly
128400301,12840030,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,14.0,DF,Y,U,,,22200.0,1.0,DF,,/wk,2016,Q4,Vomiting,,2016,Q4,1,I,20160916.0,20161006.0,20161012,20161012,EXP,,DE-ASTRAZENECA-2016SF06849,ASTRAZENECA,,65.0,YR,,F,Y,96.0,KG,20161012.0,,,DE,DE,2016,Q4,Elderly
128450923,12845092,12,C,Exenatide,EXENATIDE,1,Subcutaneous,2 MG,,,,,,,,2.0,MG,UNKNOWN,/wk,2016,Q4,Pancytopenia,,2016,Q4,3,F,20161001.0,20161130.0,20161013,20161205,EXP,,US-CELGENEUS-USA-2016101090,CELGENE,,67.0,YR,,F,Y,,,20161205.0,,OT,US,US,2016,Q4,Elderly
128450923,12845092,12,C,Exenatide,EXENATIDE,1,Subcutaneous,2 MG,,,,,,,,2.0,MG,UNKNOWN,/wk,2016,Q4,Septic shock,,2016,Q4,3,F,20161001.0,20161130.0,20161013,20161205,EXP,,US-CELGENEUS-USA-2016101090,CELGENE,,67.0,YR,,F,Y,,,20161205.0,,OT,US,US,2016,Q4,Elderly
128522911,12852291,2,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 MUG, BD",,,,,,,,10.0,UG,,,2016,Q4,Abdominal pain,,2016,Q4,1,I,20161005.0,20161009.0,20161017,20161017,EXP,,AU-AMGEN-AUSSP2016140508,AMGEN,,69.0,YR,E,F,Y,,,20161016.0,,MD,AU,AU,2016,Q4,Elderly
128522911,12852291,2,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 MUG, BD",,,,,,,,10.0,UG,,,2016,Q4,Biopsy lymph gland,,2016,Q4,1,I,20161005.0,20161009.0,20161017,20161017,EXP,,AU-AMGEN-AUSSP2016140508,AMGEN,,69.0,YR,E,F,Y,,,20161016.0,,MD,AU,AU,2016,Q4,Elderly
128522911,12852291,2,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 MUG, BD",,,,,,,,10.0,UG,,,2016,Q4,High frequency ablation,,2016,Q4,1,I,20161005.0,20161009.0,20161017,20161017,EXP,,AU-AMGEN-AUSSP2016140508,AMGEN,,69.0,YR,E,F,Y,,,20161016.0,,MD,AU,AU,2016,Q4,Elderly
128522911,12852291,2,C,EXENATIDE,EXENATIDE,1,Subcutaneous,"10 MUG, BD",,,,,,,,10.0,UG,,,2016,Q4,Nausea,,2016,Q4,1,I,20161005.0,20161009.0,20161017,20161017,EXP,,AU-AMGEN-AUSSP2016140508,AMGEN,,69.0,YR,E,F,Y,,,20161016.0,,MD,AU,AU,2016,Q4,Elderly
128644741,12864474,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,,,2016,Q4,Hyperkalaemia,,2016,Q4,1,I,20160816.0,,20161018,20161018,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20160829.0,N,PH,US,US,2016,Q4,Adult
128644741,12864474,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,,,,,,,,,2.0,MG,,,2016,Q4,Pancreatitis acute,,2016,Q4,1,I,20160816.0,,20161018,20161018,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20160829.0,N,PH,US,US,2016,Q4,Adult
128857281,12885728,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE A WEEK,0.0,,Y,U,,,,,,,,2016,Q4,Renal oncocytoma,,2016,Q4,1,I,20110731.0,20110902.0,20161026,20161026,EXP,,US-ASTRAZENECA-2011BM10445,ASTRAZENECA,,19268.0,DY,,M,Y,120.6,KG,20161026.0,,MD,US,US,2016,Q4,Elderly
128996601,12899660,18,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q4,Injection site nodule,,2016,Q4,1,I,20161001.0,,20161031,20161031,DIR,US-FDA-354490,,FDA-CTU,,68.0,YR,,M,N,79.2,KG,20161031.0,N,CN,US,US,2016,Q4,Elderly
128996601,12899660,18,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,,,2016,Q4,Skin mass,,2016,Q4,1,I,20161001.0,,20161031,20161031,DIR,US-FDA-354490,,FDA-CTU,,68.0,YR,,M,N,79.2,KG,20161031.0,N,CN,US,US,2016,Q4,Elderly
129726051,12972605,2,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,2.0,MG,,,2016,Q4,Blood pressure decreased,,2016,Q4,1,I,,20160725.0,20161124,20161124,PER,,US-ALVOGEN-2016-ALVOGEN-026862,ALVOGEN,,55.0,YR,,M,Y,120.2,KG,20161124.0,,CN,US,US,2016,Q4,Adult
129726051,12972605,2,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,2.0,MG,,,2016,Q4,Heart rate decreased,,2016,Q4,1,I,,20160725.0,20161124,20161124,PER,,US-ALVOGEN-2016-ALVOGEN-026862,ALVOGEN,,55.0,YR,,M,Y,120.2,KG,20161124.0,,CN,US,US,2016,Q4,Adult
129749292,12974929,3,C,Exenatide,EXENATIDE,1,Unknown,"2 MG, WEEKLY",,,,,,,,2.0,MG,,,2016,Q4,Condition aggravated,,2016,Q4,2,F,20161107.0,20161114.0,20161125,20161212,EXP,,US-AEGERION PHARMACEUTICAL INC.-AEGR002835,AEGERION,,58.0,YR,,F,Y,50.6,KG,20161212.0,,MD,US,US,2016,Q4,Adult
129749292,12974929,3,C,Exenatide,EXENATIDE,1,Unknown,"2 MG, WEEKLY",,,,,,,,2.0,MG,,,2016,Q4,Dermatofibrosarcoma protuberans,,2016,Q4,2,F,20161107.0,20161114.0,20161125,20161212,EXP,,US-AEGERION PHARMACEUTICAL INC.-AEGR002835,AEGERION,,58.0,YR,,F,Y,50.6,KG,20161212.0,,MD,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Blood cholesterol increased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Blood glucose decreased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Blood glucose increased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Body height decreased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Drug effect decreased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Dyspnoea,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Feeling abnormal,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Heart rate decreased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Injection site pain,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Nausea,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Product quality issue,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Underdose,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Vomiting,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
129966051,12996605,5,C,"EXENATIDE 10mcg PEN, DISPOSABLE DEVICE",EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Weight decreased,,2016,Q4,1,I,2006.0,20070815.0,20161204,20161204,PER,,US-ASTRAZENECA-2007BM13360,ASTRAZENECA,,58.0,YR,,F,Y,54.4,KG,20161205.0,,CN,US,US,2016,Q4,Adult
130009741,13000974,3,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,U,,,,,,,,2016,Q4,Diabetes mellitus inadequate control,,2016,Q4,1,I,,20161122.0,20161206,20161206,EXP,,IT-AUROBINDO-AUR-APL-2016-14817,AUROBINDO,"ALFIDI P ET AL.,. MEDIA. 2016;16:135",64.0,YR,,F,Y,,,20161206.0,,OT,IT,IT,2016,Q4,Adult
130009741,13000974,3,C,EXENATIDE,EXENATIDE,1,Unknown,,,,,U,,,,,,,,2016,Q4,Nausea,,2016,Q4,1,I,,20161122.0,20161206,20161206,EXP,,IT-AUROBINDO-AUR-APL-2016-14817,AUROBINDO,"ALFIDI P ET AL.,. MEDIA. 2016;16:135",64.0,YR,,F,Y,,,20161206.0,,OT,IT,IT,2016,Q4,Adult
130062092,13006209,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE WEEKLY,,,Y,U,,,22200.0,,,,,2016,Q4,Diabetes mellitus inadequate control,,2016,Q4,2,F,,20161212.0,20161207,20161220,EXP,,IT-ASTRAZENECA-2016SF27352,ASTRAZENECA,,64.0,YR,,F,Y,,,20161221.0,,,IT,IT,2016,Q4,Adult
130062092,13006209,1,PS,EXENATIDE,EXENATIDE,1,Subcutaneous,ONCE WEEKLY,,,Y,U,,,22200.0,,,,,2016,Q4,Nausea,,2016,Q4,2,F,,20161212.0,20161207,20161220,EXP,,IT-ASTRAZENECA-2016SF27352,ASTRAZENECA,,64.0,YR,,F,Y,,,20161221.0,,,IT,IT,2016,Q4,Adult
130149631,13014963,5,C,EXENATIDE,EXENATIDE,1,Oral,"2 MG, QD",,,U,,,,,2.0,MG,,QD,2016,Q4,Joint injury,,2016,Q4,1,I,20141126.0,20141218.0,20161210,20161210,EXP,,PHHO2014GB017051,NOVARTIS,,41.0,YR,,M,Y,117.4,KG,20161210.0,,MD,GB,GB,2016,Q4,Adult
130149631,13014963,5,C,EXENATIDE,EXENATIDE,1,Oral,"2 MG, QD",,,U,,,,,2.0,MG,,QD,2016,Q4,Psoriasis,,2016,Q4,1,I,20141126.0,20141218.0,20161210,20161210,EXP,,PHHO2014GB017051,NOVARTIS,,41.0,YR,,M,Y,117.4,KG,20161210.0,,MD,GB,GB,2016,Q4,Adult
130149631,13014963,5,C,EXENATIDE,EXENATIDE,1,Oral,"2 MG, QD",,,U,,,,,2.0,MG,,QD,2016,Q4,Psoriatic arthropathy,,2016,Q4,1,I,20141126.0,20141218.0,20161210,20161210,EXP,,PHHO2014GB017051,NOVARTIS,,41.0,YR,,M,Y,117.4,KG,20161210.0,,MD,GB,GB,2016,Q4,Adult
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Abdominal pain upper,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Blood glucose increased,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Device malfunction,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Diarrhoea,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Injection site haemorrhage,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Injection site nodule,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Insomnia,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Nausea,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
130757681,13075768,7,C,EXENATIDE,EXENATIDE,1,,,,,,,,,,,,SOLUTION FOR INJECTION,,2016,Q4,Renal colic,,2016,Q4,1,I,201604.0,20100630.0,20161230,20161230,PER,,US-ASTRAZENECA-2010BM07634,ASTRAZENECA,,836.0,MON,,F,Y,89.8,KG,20161230.0,,,US,US,2016,Q4,Elderly
